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Abstract 
 
Biotin is a cofactor required for function of essential biotin dependent enzymes 
that are involved in metabolic processes including fatty acid biosynthesis, 
gluconeogenesis, and amino acid catabolism. In order for biotin to act as a cofactor it 
must first be covalently attached to the biotin dependent enzyme. Biotin protein ligase 
(BPL) catalyzes this covalent attachment in a two-step reaction. First BPL binds biotin 
and ATP to synthesize the intermediate biotinoyl-AMP, releasing pyrophosphate. In the 
second half reaction a conserved lysine residue from the biotin dependent enzyme acts as 
a nucleophile and attacks the mixed anhydride of biotinoyl-AMP to give the biotinylated 
protein and release of AMP. Microbial BPLs are classified into two groups. Both group I 
and group II BPLs have catalytic cores and C-terminal domains that are well conserved 
between the groups. Group II biotin protein ligases are characterized by the presence of 
an N-terminal DNA binding domain that functions in transcriptional regulation of the 
genes of biotin biosynthesis. 
Escherichia coli BPL, called BirA, is the best-studied example of how an enzyme 
can also act as a transcriptional regulator of the biotin biosynthetic operon. 
Transcriptional repression of the E. coli biotin operon occurs when biotin acceptor 
proteins (biotin dependent enzymes) have been fully biotinylated thereby allowing BirA 
to accumulate biotinoyl-AMP in its active site. The presence of biotinoyl-AMP results in 
BirA dimerization and subsequent DNA binding that represses transcription of the biotin 
biosynthetic operon. Derepression of the biotin operon transcription occurs upon low 
biotin levels or increased levels of unmodified biotin acceptor proteins. Transfer of 
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accumulated biotinoyl-AMP to acceptor proteins results in monomeric BirA which is 
unable to bind the biotin operator. The N-terminal DNA binding domain of E. coli BirA 
is separated from the central domain by a linker region. It was proposed that E. coli BirA 
could be transformed into a group I BPL by simply removing the N-terminal DNA 
binding domain, where it would no longer have regulatory activity but would retain ligase 
activity. However, the E. coli BirA ligase activity was severely compromised when the 
N-terminal domain was removed, suggesting interdomain communication is required 
between the DNA binding domain and the central domain for normal ligase activity. 
The Bacillus subtilis BPL, BirA, is also classified as a Group II BPL based on 
sequence predictions of an N-terminal helix-turn-helix motif and mutational alteration of 
its regulatory properties. We report evidence that B. subtilis BirA is a Group II BPL that 
regulates transcription at three genomic sites: bioWAFDBI, yuiG and yhfUTS. Moreover, 
unlike the paradigm Group II BPL, E. coli BirA, the N-terminal DNA binding domain 
can be deleted from Bacillus subtilis BirA without adverse effects on its ligase function. 
This is the first example of successful conversion of a Group II BPL to a Group I BPL 
with retention of full ligase activity. 
The Staphylococcus aureus Group II BPL, BirA, has been reported to bind an 
imperfect inverted repeat located upstream of the biotin synthesis operon. DNA binding 
by other Group II BPLs requires dimerization of the protein, which is triggered by 
synthesis of biotinoyl-AMP (biotinoyl-adenylate), the intermediate in the ligation of 
biotin to its cognate target proteins. However, the S. aureus BirA was reported to 
dimerize and bind DNA in the absence of biotin or biotinoyl-AMP (85). These in vitro 
results argued that the protein would be unable to respond to the levels of biotin or 
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acceptor proteins and thus would lack the regulatory properties of the other characterized 
BirA proteins. We tested the regulatory function of the S. aureus protein using an in vivo 
model system and examined its DNA binding properties in vitro using electrophoretic 
mobility shift and fluorescence anisotropy analyses. We report that the S. aureus BirA is 
an effective regulator of biotin operon transcription and that the prior data can be 
attributed to artifacts of mobility shift analyses. We also report that deletion of the DNA 
binding domain of the S. aureus BirA results in loss of virtually all of its ligation activity. 
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Chapter 1 
Introduction 
 
Physiological Importance of Biotin 
Biotin is a cofactor for essential biotin dependent carboxylases, transcarboxylases, 
and decarboxylases that are involved in metabolic processes including fatty acid 
biosynthesis, gluconeogenesis, and amino acid catabolism (57). Biotin dependent 
carboxylases include acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA 
carboxylase, and 3-methylcrotonyl-CoA carboxylase. Acetyl-CoA carboxylase catalyzes 
the carboxylation of acetyl-CoA to form malonyl-CoA, the first committed step in fatty 
acid biosynthesis (Figure 1.1). Pyruvate carboxylase catalyzes the carboxylation of 
pyruvate to form oxaloacetate, to replenish oxaloacetate in the citric acid cycle. 
Propionyl-CoA carboxylase catalyzes the carboxylation of propionyl-CoA to form (S)-
methylmalonyl-CoA, an important step in forming gluconeogenic intermediates from 
catabolism of fatty acids and amino acids. Methylcrotonyl-CoA carboxylase catalyzes the 
carboxylation of methylcrotonyl-CoA to form methylglutaconyl-CoA, a step in the 
pathway of leucine catabolism. Biotin is also a cofactor for transcarboxylase, which is 
involved in the synthesis of propionic acid by Propionibacterium sherminii. Biotin is also 
required for oxaloacetate decarboxylase, which converts oxaloacetate to pyruvate. Biotin 
dependent carboxylases typically have three subunits: biotin carboxylase (BC), biotin 
carboxyl carrier protein (BCCP) (also called acceptor protein), and carboxyltransferase 
(CT) (5). Biotin is covalently attached to a conserved lysine residue of BCCP and acts as 
a swinging arm between BC and CT subunits (72). In the BC subunit, a carboxyl group is 
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transferred from a donor molecule to the nitrogen of the ureido moiety of biotin. Biotin 
transiently carries this carboxyl group to the CT subunit where it is transferred to the 
acceptor molecule (5). 
Biotin is also associated with three other proteins: biotinidase, avidin and 
streptavidin. Biotinidase catalyzes the cleavage of biotin from proteins for reuse. Because 
humans are biotin auxotrophs, mutations in the gene encoding biotinidase can lead to 
multiple carboxylase deficiency (11). Supplementation of biotin alleviates these 
symptoms (11). Avidin is a biotin binding protein that is produced in the oviducts of 
birds, reptiles and amphibians. Avidin binds biotin with high affinity and specificity with 
a dissociation constant of Kd = 10-15 M, one of the strongest non-covalent bonds known 
(50). The function of avidin is proposed to be a bacterial growth-inhibitor. Streptavidin, a 
similar protein with similar affinity for biotin, is produced by Streptomyces avidinii and 
thought to inhibit growth of competing bacteria (24). Both avidin and streptavidin are 
used extensively in biotechnology (53, 59, 67). 
 
Biotin Biosynthesis 
Biotin dependent enzymes are found across all three domains of life. Many 
bacteria, archaea, fungi and plants synthesize biotin, while other organisms are biotin 
auxotrophs, acquiring biotin from diet or microbiota. The complete biotin synthesis 
pathway has been determined in E. coli where the biotin biosynthetic operon is bi-
directional and consists of bioA to the left, and bioB, bioF, bioC, and bioD to the right. A 
sixth gene, bioH, is also required for biotin synthesis and is found outside of this operon. 
BioC and BioH catalyze pimeloyl-ACP synthesis. BioC is a methyltransferase that 
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catalyzes methyl esterification of the methyl moiety of malonyl-acyl carrier protein (62). 
Malonyl-ACP methyl ester enters the fatty acid biosynthesis pathway and undergoes two 
rounds of elongation to give pimeloyl-ACP methyl ester (62). BioH cleaves the methyl 
ester, blocking further elongation in the fatty acid biosynthesis pathway, to give 
pimeloyl-ACP (62). BioF converts pimeloyl-ACP to 7-keto-8-aminopelargonic acid	
(KAPA). BioA converts KAPA to 7,8-diaminopelargonic Acid (DAPA). BioD converts 
DAPA to dethiobiotin (DTB) and BioB converts DTB to biotin. The later steps of biotin 
synthesis, BioFADB, are well conserved whereas pimelate synthesis is quite diverse. 
Some organisms that contain the bioC gene do not have a bioH gene but have a different 
gene that encodes an esterase responsible for cleaving pimeloyl-ACP methyl ester. For 
example, Haemophilus influenzae and Campylobacter jejuni have bioG; Bacteroides 
fragilis has a fusion of bioG and bioC (83). Prochlorococcus marinus has bioK (83), 
Helicobacter pylori has bioV (15), and Francisella species contain bioJ instead of bioH 
(43). B. subtilis lacks both bioC and bioH genes and instead has bioW, encoding a 
pimeloyl-CoA synthetase, and bioI, encoding a cytochrome P450 enzyme (63). Pimelate 
synthesis in B. subtilis is still not well understood.  
 
Discovery of the Biotin Protein Ligase, BirA 
In 1972 Campbell and coworkers isolated an E. coli mutant, bir (for biotin 
retention), which required high concentrations of biotin for growth. In a biotin auxotroph 
the bir mutant is deficient in biotin uptake and requires high concentrations of biotin (19). 
In a biotin prototroph the bir mutation causes derepression of the biotin operon leading to 
overproduction and excretion of biotin (19). By selecting for resistance to a biotin 
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analogue, Pai isolated a similar E. coli mutant, bioR, which derepressed transcription of 
the biotin operon at all biotin concentrations (69). The bioR mutant differed from the bir 
mutant in that the biotin requirement and biotin uptake were normal. Because of these 
distinct phenotypic differences, Pai proposed that these two mutations affected different 
genes. 
In 1975 Eisenberg and coworkers compared 7,8-diaminopelargonic acid 
aminotransferase (BioA) and dethiobiotin synthetase (BioD) activities in E. coli wild 
type, bioR mutant, and bir mutant strains. At 5 µM biotin, a concentration that allows full 
transcriptional repression of the biotin operon in wild type, the bir mutant strain was 70% 
repressed while the bioR mutant strain was completely derepressed (42). This suggested 
that the bir mutant still had some regulatory function when the biotin uptake deficiency 
was overcome by a high biotin concentration but that the bioR mutant no longer had any 
regulation of the biotin operon. This raised further questions on how the original bir 
mutation (now designated birA1) was causing derepression of the biotin operon and 
inability to grow at normal biotin concentrations. Was the bir mutation a different 
alteration of the bioR gene or did it define a nearby gene that was somehow affecting 
BioR function?  
To answer these questions, Campbell and coworkers mutagenized an E. coli 
biotin auxotroph strain (R901) and grew survivors at 80 nM biotin (20). These survivors 
were then screened for failure to grow at 2 nM biotin (20). From this method, several 
other bir mutations were isolated and classified into three groups: birA, linked to argH at 
77 min, birB, linked to metE at 84 min, and birC, a double mutant of birB and another 
metE linked mutation (20). The birA mutants were found to be derepressed biotin operons 
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at biotin concentrations that cause repression in wild type and were also found to require 
elevated biotin concentrations for normal growth. The birB mutants were found to have a 
defect in biotin transport subsequently causing derepression of the biotin operon and the 
requirement for higher biotin concentrations for growth. The birC mutants were found to 
be double mutants with one mutation in birB and another temperature sensitive metE-
linked mutation. Trying to determine why these mutants had growth defects at low biotin 
concentrations, they tested for the ability to catalyze the covalent attachment of labeled 
biotin to acetyl-CoA carboxylase and found that extracts from most of the birA mutants 
had no activity. Extracts from birB and birC mutants had wild type activity. They 
proposed that the birA gene product was responsible for both the covalent attachment of 
biotin to acceptor proteins and the regulation of the biotin operon. By 1981 it was clear 
that BirA has both of these activities after Barker and Campbell purified BirA and 
showed in vitro biotinylation of acetyl-CoA carboxylase and DNA binding activity to a 
biotin operon sequence (8, 10). BirB, now known as YigM, was later characterized as a 
membrane protein with ten transmembrane α-helices that is responsible for biotin 
transport (77). 
 
Diversity of Biotin Protein Ligases 
Genomic sequencing and comparative genomic analyses have identified biotin 
protein ligases (BPLs) in all three domains of life, which have been classified into four 
groups. All four groups contain the conserved catalytic and C-terminal domains but 
exhibit diversity in the N-terminal region. Group I BPLs are found in bacteria and 
archaea and only contain the conserved catalytic domain and the C-terminal domain (79). 
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Group II BPLs are found in bacteria and archaea and have an N-terminal helix-turn-helix 
DNA binding domain that is responsible for transcriptional regulation of the biotin 
operon (79). Group III BPLs are found in plants and have a small N-terminal domain that 
is responsible for organelle targeting (2, 93). Group IV BPLs are found in eukaryotes and 
have an extended N-terminal domain that does not resemble a DNA binding domain (68). 
The extended N-terminal domain of the human BPL is proposed to play a role in acceptor 
protein recognition (56). While most organisms have one BPL, Francisella novicida, 
Clostridium acetobutuylicum, Lactococus lactis, Halobacterium sp., Pyrococcus abyssii, 
and Pyrococcus furiosus have a group I and a group II BPL (45, 79, 102). Differences in 
BPL dimerization have also been observed. The group I BPLs from Mycobacterium 
tuberculosis (65) and Aquifex aeolicus (94) are found to be primarily monomeric with or 
without biotinoyl-AMP bound in the active site. However, the group I BPL from 
Pyrococcus horikoshii is a dimer in the presence or absence of biotinoyl-AMP (6). The 
group II BPL, BirA, from E. coli is monomeric in the unliganded form and when biotin is 
bound. Dimerization is only observed when biotinoyl-AMP is active site bound (89). 
 
The Biotin Protein Ligase Reaction  
 In order for biotin to act as a cofactor it must first be covalently attached to the 
biotin dependent enzymes. Biotin protein ligase catalyzes this essential covalent 
attachment in a two-step reaction (Figure 1.2). First BPL binds biotin and ATP to 
synthesize the biotinoyl-AMP intermediate, with release of pyrophosphate (29). In the 
second half reaction the ε-amino group of a conserved lysine residue from BCCP acts as 
a nucleophile and attacks the mixed anhydride of biotinoyl-AMP to give biotinylated 
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BCCP and the release of AMP (29). This reaction is extraordinarily specific as E. coli 
only has a single biotinylated enzyme and other organisms only contain up to five 
biotinylated proteins (29). The biotinylated lysine is part of a conserved AMKM 
tetrapeptide and acceptor proteins from other organisms are recognized and biotinylated 
by the E. coli BirA (29).  
The biotin protein ligase reaction is useful in biotechnology for the labeling of 
proteins and peptides (37). Schatz developed small, unstructured peptides that are still 
recognized and biotinylated by E. coli BirA (82). Schatz peptides can be fused to a 
protein of interest, become biotinylated upon expression of E. coli BirA, and can be 
detected with avidin or streptavidin antibodies or purified with avidin or streptavidin 
columns (37). The biotin protein ligase reaction has also been adapted for proximity-
dependent biotin identification (BioID) in eukaryotic cells (81). A promiscuous mutant 
version of E. coli BirA (R118G) is fused to a target protein and biotinylates proteins that 
interact with the target protein (30, 35, 81). The biotinylated proteins are then isolated 
with avidin or streptavidin columns and identified by mass spectrometry.  
 
Transcriptional Regulation of the Biotin Operon  
 Biotin synthesis is expensive and therefore it is not surprising that organisms 
capable of biotin synthesis also have a mechanism to regulate this pathway. The E. coli 
biotin operon is a bidirectional operon with bioA transcribed to the left and bioBFCD 
transcribed to the right. Transcription is repressed in both directions when a high 
concentration of biotin is added to E. coli cultures (36). Transcription from both 
promoters is highest when an E. coli biotin auxotroph is starved for biotin in minimal 
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media (36). After these early transcription studies and isolation of the bir mutant, it 
appeared that BirA was a TrpR like repressor where it only binds DNA when bound with 
biotin. However, in 1979 Prakash and Eisenberg found that the co-repressor is not biotin 
but biotinoyl-AMP, the product of the first half reaction in the covalent attachment of 
biotin to acceptor proteins (75). In 1988, Cronan demonstrated that the level of repression 
of the E. coli biotin operon was sensitive to the level of apo acceptor protein (38). An 
increase in apo acceptor protein consumed BirA bound biotinoyl-AMP, causing 
dissociation of BirA from the biotin operator and derepression of the biotin synthesis 
genes (38). Dimerization and DNA binding studies by Streaker and Beckett found that E. 
coli BirA only efficiently dimerizes when biotinoyl-AMP is bound in the active site and 
that dimerization is required for DNA binding (89). These findings gave rise to the 
current model of transcriptional regulation of the E. coli biotin operon (Figure 1.3) (36). 
Under limiting biotin concentrations the small amount of biotinoyl-AMP synthesized by 
BirA is quickly attacked by the pool of apo AccB. Without biotinoyl-AMP bound in the 
active site, BirA cannot dimerize and therefore does not bind to the biotin operator. This 
allows transcription of the biotin operon in both directions. Under excess biotin 
concentrations the pool of AccB is sufficiently biotinylated allowing biotinoyl-AMP to 
accumulate in the BirA active site. This causes dimerization of BirA and subsequent 
binding to the biotin operator where transcription is repressed in both directions.  
Comparative genomic analysis of organisms with group I BPLs, lacking the N-
terminal DNA binding domain, have identified new transcriptional regulators of biotin 
synthesis and biotin transport genes. Alphaproteobacteria were found to have a GntR-
type transcription factor, BioR, near biotin biosynthesis genes (80). BioR contains a 
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conserved helix-turn-helix DNA binding domain. Upstream regions of biotin biosynthesis 
genes were found to contain a palindromic consensus sequence called BIOR box (80). 
Electrophoretic mobility shift assays (EMSA) show that BioR binds BIOR box in a 
concentration dependent manner (44). Deletion of bioR showed a 1.5-fold increase in 
transcription of the biotin operon and overexpression of BioR showed a 10-fold decrease 
in biotin operon transcription indicating that BioR acts as a repressor (44). Transcription 
of the biotin operon decreases with increasing exogenous biotin concentrations indicating 
that regulation is biotin dependent (44). However, no regulatory ligand was found to be 
associated with BioR and it is still unclear how biotin is involved in regulation. 
Comparison of Actinobacteria genomes revealed genes encoding a transcriptional 
regulator from the TetR family, BioQ, are localized near biotin synthesis and transport 
genes (18). Palindromic 13-base pair BioQ DNA binding sites were also found upstream 
of biotin synthesis and biotin transport genes, and EMSAs show that Corynebacterium 
glutamicum BioQ does bind to these sites (18). Growth of C. glutamicum in excess biotin 
or biotin-limiting conditions only showed a moderate change in transcription of biotin 
related genes (18). Deletion of BioQ resulted in a large increase in transcription of biotin 
synthesis and biotin transport genes (18). However, the mechanism and regulatory ligand 
of BioQ are still unknown.  
 
Two Competing Models for the E. coli BirA Molecular Switch  
 Weaver and coworkers argue that the molecular switch of BirA from 
transcriptional regulator to ligase enzyme is controlled by two competing protein-protein 
interactions (95). Trying to determine how BirA interacts with acceptor proteins, they 
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aligned the crystal structure of AccB with the crystal structure of biotin bound BirA so 
that the biotinylated lysine residue of AccB is positioned close to the biotin in BirA. 
Based on the alignment models, the β-sheet strand Lys122-Glu128 of AccB can form a 
parallel β-sheet with strand Val189-Lys194 of BirA to form a heterodimer. This same β-
strand, Val189-Lys194, of BirA is found to form an antiparallel β-sheet with the same 
strand in a second BirA to form a homodimer. This model suggests that 
heterodimerization of BirA with AccB and homodimerization of BirA are mutually 
exclusive. Therefore when apo AccB concentration increases, heterodimerization with 
biotinoyl-AMP bound BirA occurs, preventing homodimerization and subsequent DNA 
binding. Heterodimerization of BirA with AccB allows transcription of biotin synthesis 
genes to sufficiently biotinylate AccB. When AccB synthesis is decreased, biotinoyl-
AMP bound BirA is free to homodimerize and bind the biotin operon to prevent 
transcription of biotin synthesis genes. 
Solbiati and Cronan argue that the molecular switch does not require extensive 
protein-protein interactions (87). They suggest that in the protein-protein interaction 
model the heterodimer between BirA and AccB must be long lived in order to 
outcompete homodimerization of BirA. Due to this long interaction it should be possible 
to directly detect the heterodimer. Since there has been no direct detection of the 
heterodimer Solbiati and Cronan argue that this is a major caveat to the protein-protein 
interaction model. In their experiment, Solbiati and Cronan show that the molecular 
switch from transcriptional regulator to ligase enzyme still occurs when they express 
small (14-15 residue) synthetic biotin acceptor proteins (Schatz peptides) that have 
extremely different sequences and structures from the natural acceptor protein. Many of 
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the AccB residues that are proposed to interact with BirA are missing in the Schatz 
peptides. In addition, no residue besides the biotinylated lysine is conserved in the 
AMKM tetrapeptide. Solbiati and Cronan propose that biotinoyl-AMP levels control the 
molecular switch. In this model, the switch is the removal of biotinoyl-AMP from the 
BirA active site by biotinylation of acceptor protein. The acceptor protein binds BirA, 
accepts the biotin molecule, and rapidly dissociates to leave BirA in the unliganded form 
preventing dimerization and subsequent DNA binding. Dimerization of BirA would only 
occur after the pool of acceptor proteins have been biotinylated, which allows biotinoyl-
AMP to accumulate in the BirA active site. 
 
The E. coli BirA N-Terminal DNA Binding Domain is Required for Ligase Activity 
 The crystal structure of E. coli BirA showed three distinct domains: N-terminal 
DNA binding domain, central catalytic domain, and a small C-terminal domain (Figure 
1.4) (96). It appears that the N-terminal domain of E. coli BirA is well separated from the 
central domain by a linker region. Xu and Beckett proposed that E. coli BirA could be 
transformed into a group I BPL by simply removing the N-terminal DNA binding 
domain, where it would no longer have regulatory activity but would retain ligase activity 
(100). However, the ligase activity was severely compromised when the N-terminal 
domain was removed, suggesting interdomain communication is required between the 
DNA binding domain and the central domain for normal ligase activity (100).  
Experiments investigating the role of the wing in the winged helix-turn-helix 
DNA binding domain also support the idea that interdomain communication is required 
for ligase activity. When the wing from the winged helix-turn-helix motif was deleted, 
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DNA binding activity was lost and surprisingly ligase activity was also 
compromised (26). Replacing the native wing with a wing from another helix-turn-helix 
transcription factor, OmpR, largely restored ligase activity but not DNA binding activity 
(26). This indicates that in the absence of DNA binding the wing is involved in active site 
organization. This also supports the idea that the BirA wing is required for specific 
interaction with the biotin operator. However, despite many attempts, there is no crystal 
structure of BirA bound to the operator and therefore the exact interaction is still 
unknown. 
 
Function of E. coli BirA C-Terminal Domain 
The C-terminal domain is found in all four BPL groups but the function has long 
been unknown. Experiments investigating the interaction between E. coli BirA and AccB 
have given us some clues. Mutant AccB having the substitutions E119K and E147K are 
poorly biotinylated by BirA (27). Complementary charge substitution mutations in BirA 
did not restore wild type levels of biotinylation. However, a mutant with a substitution in 
the C-terminal domain of BirA (K277E) was able to biotinylate the mutant AccB better 
than wild type BirA (27). This indicates that K277 may play a role in substrate 
recognition. Further mutational analysis found that a single amino acid substitution in the 
E. coli BirA C-terminal domain (R317E) was found to decrease affinity for ATP 25-fold 
and decrease ligase activity 10-fold (27). A mutant with a truncation of the C-terminal 
domain at I272 no longer had any ligase activity (27). However, it is unclear if the C-
terminal truncation is defective in AccB interaction, synthesis of biotinoyl-AMP, or both. 
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Based on these data, the C-terminal domain is required for ligase activity and may play a 
role in binding ATP and interacting with acceptor protein.  
Chakravartty and Cronan isolated mutations in E. coli birA that enhanced DNA 
binding activity. Surprisingly, one such mutant K267M mapped to the linker between the 
central domain and the C-terminal domain (25). Based on the crystal structure, this 
residue is solvent exposed and is not located near the dimer interface or the DNA binding 
domain but is somehow impacting operator binding. They propose that this substitution is 
interfering with interdomain communication (25). Based on these studies and those of N-
terminal deletions, E. coli BirA has extensive interdomain communication between all 
three domains.  
 
Specific Aims of This Work 
Before the studies in this thesis the regulatory function of group II BPLs had only 
been extensively studied in E. coli BirA. The entire model of group II BPL regulatory 
function has been based on E. coli BirA. Sequence alignments of E. coli BirA to other 
group II BPLs show low sequence identity and could potentially lead to differences in 
regulatory function. The Bacillus subtilis group II BPL, BirA, has 27% sequence identity 
to E. coli BirA and was found to play a biotin dependent role in regulation of the biotin 
operon (16, 17, 73). Unlike E. coli, three operons in B. subtilis are regulated by biotin 
(61). In contrast to E. coli, the B. subtilis biotin operon is unidirectional and contains 
bioW and bioI (16, 73). The other two operons include putative biotin transport genes 
(yhfU and yuiG) and putative fatty acid biosynthesis genes (yhfT and yhfS) (61). Also 
unlike E. coli, B. subtilis has three biotin dependent enzymes: acetyl-CoA carboxylase, 
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pyruvate carboxylase, and propionyl-CoA carboxylase (55). Could these additional 
factors influence transcriptional regulation of the biotin operon? This work looked to 
determine if other group II BPLs followed the E. coli model of transcriptional regulation 
of the biotin operon. I focused on several aspects of the regulatory model including 
dimerization, co-repressor identification, DNA binding, and response to increased levels 
of apo acceptor proteins. In addition, I examined if other group II BPLs require 
interdomain communication between the N-terminal DNA binding domain and the 
catalytic central domain for proper ligase activity or if this interdomain communication 
was specific to only E. coli BirA.  
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Figures 
 
Figure 1.1. Role of biotin in acetyl-CoA carboxylase. Acetyl-CoA carboxylase has 
three subunits: biotin carboxylase (BC), biotin carboxyl carrier protein (BCCP), and 
carboxyltransferase (CT) (5). Biotin is covalently attached to a conserved lysine residue 
of BCCP and acts as a swinging arm between BC and CT (72). In the BC subunit, a 
carboxyl group is transferred from a donor molecule to the nitrogen of the ureido moiety 
of biotin (5). Biotin transiently carries this carboxyl group to the CT subunit where it is 
transferred to the acetyl-CoA to form malonyl-CoA (5). This is the first committed step 
of fatty acid biosynthesis.  
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Figure 1.2. The Biotin protein ligase reaction. Biotin protein ligase catalyzes the 
covalent attachment of biotin to biotin dependent enzymes in a two step reaction. BPL 
binds biotin and ATP to synthesize the intermediate biotinoyl-AMP, releasing 
pyrophosphate. A conserved lysine residue from BCCP acts as a nucleophile and attacks 
the mixed anhydride of biotinoyl-AMP to give biotinylated BCCP and the release of 
AMP. Figure is from (54). 
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Figure 1.3. E. coli model of transcriptional regulation of the biotin operon (36).  
A. Repression by BirA. Sufficient biotin is present that essentially all acceptor protein 
(AccB) is biotinylated. B. Derepression by limited biotin results in low levels of Bio-
AMP such that BirA is unable to dimerize and exert repression. C. Derepression by an 
excess of AccB acceptor protein consumes the Bio-AMP resulting in low levels that 
preclude BirA dimerization and operator binding. Green ovals denote BirA, tailed blue 
ovals are AccB, black dots represent biotin, and black dots connected to small red 
pentagons denote biotinoyl-adenylate (Bio-AMP). Modified from reference (87). 
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Figure 1.4. Structure of E. coli BirA. E. coli BirA has three distinct domains: N-
terminal helix-turn-helix DNA binding domain, central catalytic domain, and a small C-
terminal domain. This figure was created using Chimera (74) and Protein Data Bank file 
1HXD (60). Deletion of the N-terminal domain, Δ2-65 (endpoint indicated in red), results 
in severely compromised ligase activity (100). Deletion of the wing from the helix-turn-
helix in the N-terminal domain also compromises ligase activity (26). Truncation of the 
C-terminal domain at I272 (indicated in orange) results in no ligase activity (27). 
Interdomain communication between all three domains is required for proper ligase 
activity.  
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Chapter 2 
Successful Conversion of the Bacillus subtilis BirA Group II Biotin Protein Ligase 
into a Group I Ligase1 
 
Introduction 
Biotin protein ligase (BPL) is required for the covalent attachment of biotin to 
biotin-dependent enzymes. This attachment proceeds in a two-step reaction. First, BPL 
binds both biotin and ATP to synthesize biotinoyl-5′-AMP (Bio-5ʹ-AMP, also called 
biotinoyl-adenylate) with release of pyrophosphate (29). The ε-amino group of the 
conserved lysine residue of the acceptor protein acts as a nucleophile to attack the Bio-5ʹ-
AMP mixed anhydride bond to give covalently attached biotin plus AMP (Figure 1.2). 
Microbial BPLs are readily placed into two groups (79). Both groups have catalytic and 
C-terminal domains that show strong structural conservation (7, 12, 76, 94) whereas 
Group II BPLs are characterized by addition of an N-terminal helix-turn-helix (HTH) 
DNA binding domain that permits transcriptional regulation of the biotin synthetic genes. 
E. coli BirA, the paradigm for regulation of biotin biosynthesis, is the best studied Group 
II BPL. Transcriptional repression of the E. coli biotin operon occurs when BirA 
accumulates Bio-5ʹ-AMP because all biotin acceptor proteins have been biotinylated (1, 
38, 87). Bio-5ʹ-AMP accumulation results in dimerization of BirA and subsequent DNA 
binding (13, 34). In all four E. coli BirA crystal structures (96-98) the HTH structure is 
spatially well removed from the other domains of the protein and thus deletion of the N-
terminal DNA binding domain was expected to convert this Group II BPL into a fully 
																																																								
1 This chapter was published in PLoS One (2014) 9(5):e96757. 
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functional Group I ligase. However, this was not the case: the resulting protein had 
severely compromised ligase activity (100). This was also true for ligases having smaller 
N-terminal deletions (25).  
The sequences of other Group II BPLs suggest such proteins are found in γ-
Proteobacteria, Bacilli, and Clostridii (79), although only the proteins from E. coli (12) 
and (very recently) Staphylococcus aureus (71) have been enzymatically characterized 
and crystallized. One of the Group II BPLs, B. subtilis BirA, has only 27% amino acid 
sequence identity to E. coli BirA (Figure 2.2). Despite this low sequence identity, 
Bacillus subtilis birA has been shown to complement the ligase activity of a temperature-
sensitive E. coli birA85 strain (17). Moreover, B. subtilis birA mutants show constitutive 
expression of a bioW-lacZ fusion, suggesting that BirA regulates biotin operon 
transcription (17). B. subtilis microarray data identified two additional transcripts, yuiG 
and yhfUST, regulated by biotin and BirA (61). Both YuiG and YhfU have strong 
sequence similarity to the structurally characterized BioY biotin transporter of 
Lactococcus lactis (14) and other well characterized energy-coupling factor (ECF) biotin 
transporters (52). All three transcripts have similar predicted BirA binding sites (61, 79) 
(Figure 2.3). B. subtilis has two known biotinylated proteins, pyruvate carboxylase (PyC) 
and the biotin carboxyl carrier protein (AccB) subunit of acetyl-CoA carboxylase (Figure 
2.4). A third B. subtilis protein, biotin/lipoyl attachment protein (BLAP) encoded by the 
yngHB gene was found to be biotinylated and lipoylated when expressed in E. coli (39) 
although subsequently this protein was found not to be lipoylated by the B. subtilis 
enzymes that modify the known cognate lipoic acid acceptor proteins (32). 
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A major shortcoming of our picture of the enzymatic and in vivo regulatory 
activities of Group II BPLs is that it is based on a single example, E. coli BirA. For this 
reason we decided to study the enzymatic and regulatory properties of the BirA of B. 
subtilis, a bacterium that is evolutionarily diverse from E. coli. Moreover the amino acid 
sequence of B. subtilis BirA differs markedly from that of the E. coli protein and in vivo 
B. subtilis BirA biotinylates multiple proteins whereas E. coli BirA modifies only a single 
protein. Here we report that B. subtilis BirA is a Group II BPL that follows the E. coli 
model of regulation, but unlike the E. coli protein, B. subtilis BirA can be successfully 
converted into a fully active Group I BPL.  
 
Materials and Methods 
Strains chemicals and culture media.  
The bacterial strains used were derivatives of B. subtilis 168 and E. coli K-12 
(Table 2.1). The rich medium used to grow E. coli and B. subtilis was LB. The defined 
medium for E. coli was M9 salts supplemented with 0.5% glucose and 0.01% vitamin-
free Casamino Acids (Difco) whereas the defined medium for B. subtilis was Spizizen 
salts (3) supplemented with 0.5% glycerol and 0.05% vitamin-free Casamino Acids 
(Difco) in addition to 0.01% each of tryptophan, tyrosine, isoleucine and phenylalanine. 
Antibiotics were used at the following concentrations (in µg ml-1): sodium ampicillin, 
100; kanamycin sulfate, 50; chloramphenicol, 25; tetracycline HCl, 12; erythromycin, 
100; lincomycin, 12.5; streptomycin sulfate, 50 and spectinomycin sulfate, 50. The 15:1 
mixture of ticarcillin disodium salt and potassium clavulanate (Research Products 
International) was used at 25 µg ml-1. Oligonucleotides were purchased from Integrated 
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DNA Technologies. PCR amplification was performed using Taq polymerase (New 
England BioLabs) and Pfu polymerase (Stratagene) according to the manufacturer’s 
specifications. DNA constructs were sequenced by ACGT, Inc. Reagents and chemicals 
were obtained from Sigma-Aldrich and Fisher, unless otherwise noted. New England 
BioLabs supplied restriction enzymes and T4 DNA ligase. Life Technologies provided 
SYBER Green I Nucleic Acid Gel stain and the 6% DNA Retardation Novex TBE Gels. 
Perkin Elmer provided [α-32P]ATP (6,000 Ci/mmol). Analtech TLC Uniplates of 
microcrystalline cellulose matrix were purchased from Sigma-Aldrich. 
Plasmids and plasmid constructions.  
The plasmids used and constructed are given in Table. 2.2. The B. subtilis birA 
gene was amplified by PCR from B. subtilis strain 168 genomic DNA with primers 
SKH001 and SKH002 (all primers are given in Table 2.3) that added NdeI and XhoI 
sites. The product was digested with NdeI and XhoI and ligated into the same sites of 
pET19b, with an N-terminal hexahistidine tag to give pSKH001. 
The C-terminal 86 residues of B. subtilis AccB (AccB-86) were amplified by PCR 
from B. subtilis strain 168 genomic DNA with primers SKH005 and SKH006 that added 
NcoI and XhoI sites. The product was digested with NcoI and XhoI and ligated into the 
same sites of pET-28 to give pSKH003 which encoded the untagged protein. The C-
terminal 77 residues of B. subtilis PyC (PyC-77) were amplified by PCR from B. subtilis 
strain 168 genomic DNA with primers SKH007 and SKH009 and inserted into pET-28 
by the same procedures.  
B. subtilis BirA, Δ2-64 BirA, Δ2-66 BirA, Δ2-74 BirA, and Δ1-81 BirA were 
amplified by PCR from B. subtilis strain 168 genomic DNA with forward primers 
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SKH038, SKH036, SKH046, SKH048, SKH045, respectively, plus reverse primer 
SKH037. The primers added EcoRI and SalI sites. The products were digested with 
EcoRI and SalI and ligated into the same sites of pBAD322K, to give pSKH006, 
pSKH005, pSKH009, pSKH010 and pSKH011, respectively. The products were also 
ligated into the same sites of pBAD322Cm to give pSKH013, pSKH012, pSKH016, 
pSKH017 and pAKH018, respectively. E. coli BirA and Δ2-64 BirA were amplified by 
PCR from E. coli MG1655 genomic DNA with primers SKH049 and SKH043, and 
SKH042 and SKH043, respectively, thereby adding EcoRI and SalI sites. The products 
were digested with EcoRI and SalI and ligated into the same sites of pBAD322K, to give 
pSKH008 and pSKH007 respectively. The products were also ligated into the same sites 
of pBAD322Cm to give pSKH015 and pSKH014 respectively.  
B. subtilis Δ2-64 BirA, Δ2-66 BirA, Δ2-74 BirA, and Δ1-81 BirA were amplified 
by PCR from B. subtilis strain 168 genomic DNA with forward primers SKH040, 
SKH047, SKH050, SKH044, respectively plus reverse primer SKH041. The primers 
added NdeI and XhoI sites. The products were digested with NdeI and XhoI and ligated 
into the same sites of pET-19b, adding an N-terminal hexahistidine-tag, to give 
pSKH019, pSKH020, pSKH021, and pSKH022, respectively.  
A 500 base pair internal fragment of B. subtilis bioW was PCR amplified from B. 
subtilis strain 168 genomic DNA with primers SKH057 and SKH058 that added EcoRI 
and BamHI sites. The product was digested with EcoRI and BamHI and ligated into the 
same sites of pMUTIN4 to give pSKH023.  
B. subtilis accB-86 was PCR amplified from strain 168 genomic DNA with 
primer SKH069 which added a HindIII and a strong RBS site 
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(AAGGAGGAAAAAATATG) plus primer SKH070 which contained an SphI site. The 
product was digested with HindIII and SphI and ligated into the same sites of pDR111 to 
give pSKH0024. 
Bacillus subtilis strain construction.  
B. subtilis competent cell preparation and transformation were carried out as 
described by Dubnau and Davidoff-Abelson (41). To create a bioW-lacZ chromosomal 
fusion, pSKH023 was transformed into strain 1A330 creating strain SKH001. Single 
crossover integration into bioW was verified by PCR and sequencing. To construct an 
IPTG inducible chromosomal copy of accB-86, strain SKH001 was transformed with 
linearized pSKH024 creating strain SKH002. Double crossover integration into amyE 
was verified by the amylase production screen of Harwood and Cutting (51). Integration 
was also verified by PCR and by sequencing with primers SKH065 and SKH066, 
SKH067 and SKH075 and SKH073 and SKH074. 
Structural modeling and sequence alignment.  
The B. subtilis AccB biotin attachment domain was identified by InterProScan 
(101) and structural modeling to E. coli AccB-87 crystal structure (PDB 1A6X) using 
Swiss-Model automated mode (4, 58, 70). The B. subtilis PyC biotin attachment domain 
was identified by InterProScan (101) and structural modeling to the Staphylococcus 
aureus pyruvate carboxylase biotin attachment domain crystal structure (3HBL) using 
Swiss-Model as above. B. subtilis BirA N-terminal deletions were determined by 
modeling to S. aureus BirA crystal structure (4DQ2) as a template using Swiss-Model 
automated mode as above. The final image was created using UCSF Chimera package 
(74). Sequence alignments were created using the Clustal Omega 
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(http://www.ebi.ac.uk/Tools/msa/clustalo/) and the output was processed by ESPript 3.0 
(http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi) to generate the final figure (49). 
In vivo complementation.  
Two E. coli birA strains were tested. In the more straightforward test strain 
BM4092 (9) was transformed with either plasmid pSKH001 or pSKH002 followed by 
selection for transformants by plating on LB supplemented with ampicillin or kanamycin, 
respectively. These strains were grown at 37°C on M9 minimal plates (66) with 25 µM 5-
bromo-4-chloro-indolyl-β-D-galactopyranoside (X-gal) and varying concentrations of 
biotin (1.6 nM, 4.1 nM, 41 nM, 4.1 µM, or 41 µM) (9). Note that gene expression from 
T7 promoter based multi-copy plasmids in the absence of T7 RNA polymerase has been 
shown to be equivalent to that of a single copy plasmid (88). Derivatives of strain 
BM4092 expressing the mutant BirAs encoded by kanamycin resistant plasmids 
pSKH005, pSKH006, pSKH007, pSKH008, pSKH009, pSKH010 or pSKH011 were 
similarly obtained and tested.  
 Strain VC618 which carries a deletion of the chromosomal birA gene was 
transformed with pSKH012, pSKH013, pSKH014, pSKH015, pAKH016, pSKH017, or 
pSKH018 and transformants were selected on LB plates supplemented with ampicillin 
and chloramphenicol at 30°C. These strains were cured of the temperature sensitive 
plasmid VC18 which expresses the Saccharomyces cerevisiae Bpl1 ligase by growth at 
42°C on the defined medium supplemented with chloramphenicol and biotin. Loss of the 
temperature-sensitive plasmid was indicated by ampicillin sensitivity (26). These strains 
were then grown at 37°C on M9 minimal plates (66) with 25 µM X-gal and varying 
concentrations of biotin as above (9). 
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Protein purification.  
For purification of the wild type and B. subtilis N-terminally deleted BirA 
Proteins E. coli strain BL21 (λ DE3) was transformed with pSKH001, pSKH019, 
pSKH020, pSKH021, or pSKH022. The strains were grown at 37°C in LB medium 
supplemented with ticarcillin-clavulanate to an OD600 of 0.8 and induced by addition of 
IPTG to 1 mM for an additional 6 h at 37°C. Cells were centrifuged and resuspended in 
lysis buffer which was 50 mM Tris-HCl, 500 mM NaCl, 0.1 mM tris(2-
carboxyethyl)phosphine (TCEP), 10 mM imidazole, 5% glycerol, pH 8.0). The cells were 
lysed by passage through a French pressure cell and the lysate was centrifuged. The 
supernatant was added to Ni NTA beads (Qiagen) and incubated for 30 min. The mixture 
was added to a disposable 10 ml polypropylene column (Pierce) and washed with three 
column volumes of wash buffer (50 mM Tris-HCl, 500 mM NaCl, 0.1 mM TCEP, 60 
mM imidazole, 5% glycerol, pH 8.0). BirA was eluted in 1 ml fractions with elution 
buffer (50 mM Tris-HCl, 500 mM NaCl, 0.1mM TCEP, 250 mM imidazole, 5% glycerol, 
pH 8.0). Fractions were subjected to SDS-PAGE to determine purity. Pure fractions were 
combined and dialyzed against storage buffer (50 mM Tris-HCl, 500 mM NaCl, 0.1 mM 
TCEP, 5% glycerol, pH 8.0). Aliquots were flash frozen and stored at -80°C.  
The B. subtilis acetyl-CoA carboxylase biotin carboxyl carrier protein biotin 
attachment domain (AccB-86) was purified from E. coli strain BL21 (λ DE3) 
transformed with pSKH003. The strain was grown at 37°C in LB medium supplemented 
with kanamycin to an OD600 of 0.8 and induced by addition of IPTG to 1 mM for an 
additional 4 h at 30°C. The cells were centrifuged and resuspended in starting buffer (20 
mM Tris-HCl, 1 mM NaCl, 0.1 mM TCEP, 5% glycerol, pH 8.0). The cells were lysed 
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by passage through a French pressure cell. The lysates were centrifuged and the 
supernatant was subjected to 60% isopropanol precipitation followed by anion exchange 
chromatography using a HiTrap Q FF column (GE Healthcare) and fast liquid 
chromatography (AKTA) (28, 78).  
The B. subtilis pyruvate carboxylase biotin attachment domain (PyC-77) was 
purified E. coli strain BL21 (λ DE3) transformed with pSKH004. The strain was grown at 
37°C in LB medium supplemented with kanamycin to an OD600 of 0.8 and induced by 
addition of IPTG to 1 mM for an additional 4 h at 30°C. The cell were harvested by 
centrifugation and resuspended in starting buffer (50 mM sodium acetate, 100 mM NaCl, 
0.1 mM TCEP, 5% glycerol, pH 4.9). The cells were lysed by passage though a French 
pressure cell and centrifuged. The supernatant was subjected to cation exchange 
chromatography using HiTrap SP FF column (GE Healthcare) and fast liquid 
chromatography (AKTA). PyC-77 was eluted by a NaCl gradient. Fractions were 
subjected to SDS-PAGE and fractions containing PyC-77 were combined and dialyzed 
against 50 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffer 
(pH 7.5) containing 500 mM NaCl and 0.1 mM TCEP. To further purify PyC-77 the 
protein was subjected to Superdex-75 size exclusion chromatography. Eluted fractions 
were analyzed by SDS-PAGE to determine purity. Fractions containing pure PyC-77 
were combined, dialyzed against 50 mM HEPES buffer (pH 7.5) containing 500 mM 
NaCl, 0.1 mM TCEP, and 5% glycerol, flash frozen and stored at -80°C.  
Plasmid pQC026C a derivative of vector pET28b encoding a terminal 
hexahistidine tagged BLAP was transformed into E. coli strain BL21 (λ DE3). The strain 
was grown in LB medium to an OD600 of 0.8 and induced by addition of IPTG to 1 mM 
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for an additional 4 h. BLAP was purified by Ni+2 affinity chromatography as previously 
described (32). The C-terminal hexahistidine tagged Δ2-65 BirA was purified as 
previously described (25). 
Electrophoretic Mobility Shift Assay (EMSA) of DNA binding.  
The predicted B. subtilis BirA binding sites upstream of the coding sequences of 
bioO, yhfU and yuiG were PCR amplified from B. subtilis 168 genomic DNA with 
primers SKH014 and SKH015, SKH016 and SKH017 and SKH018 and SKH019, 
respectively. A DNA fragment containing one half-site of B. subtilis bioO was similarly 
amplified with primers SKH034 and SKH035. E. coli bioO was amplified with primers 
SKH026 and SKH027 from MG1655 genomic DNA. Negative control DNA (blap) was 
amplified from B. subtilis 168 genomic DNA with primers SKH028 and SKH029. All 
DNA fragments were 125 bp in length. The PCR products were sized on a 1.8% agarose 
gel and purified using a QIAquick PCR Purification Kit (Qiagen). DNA concentrations 
were determined at OD260 by using a NanoDrop 2000c. Purified BirA was incubated with 
the small nucleophile hydroxylamine at neutral pH to cleave any Bio-5′-AMP bound in 
the active site (33) and then dialyzed against storage buffer. The reaction contained 50 
mM Tris-HCl (pH 8.0), 1 mM EDTA, 50 mM NaCl, 10% glycerol, 40 nM DNA and 
various concentrations of BirA (500 nM, 250 nM, 125 nM, 62.5 nM, 31.25 nM, 15.6 
nM), 1 mM ATP, 1 mM MgCl2, and 1 µM biotin (26). The binding reactions were 
incubated at room temperature for 30 min and then loaded into a 6% DNA retardation gel 
(Invitrogen). The gel was run in 0.5X TBE at 100 V for 85 min. The gel was stained with 
SYBR Green I nucleic acid gel stain (Invitrogen) and visualized using Bio-Rad 
Chemidoc XRS and Quantity One software. 
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Chemical cross-linking of BirA.  
Purified BirA was dialyzed against 50 mM HEPES buffer (pH 7.5) containing 
500 mM NaCl, 0.1 mM TCEP and 5% glycerol. BirA (30 µM) was incubated with or 
without biotin (0.1 mM) and ATP (0.1 mM) at room temperature for 30 min. Various 
concentrations of ethylene glycol bis[succinimidylsuccinate] (EGS) (0.125, 0.25, 0.375, 
0.5 mM) were added and incubated at room temperature for 30 min. SDS-loading dye 
was added and samples were heated to 99°C for 5 min. Samples were loaded on 4-20% 
gradient SDS polyacrylamide gels (Bio-Rad) and run at 110 v for 1 h. 
Mass spectrometry. 
Purified acceptor proteins AccB-86, PyC-77, and BLAP (10 µM), with or without 
incubation with BirA (0.5 µM), ATP (3 mM), and biotin (250 µM), were dialysed against 
2 mM ammonium acetate, dried under a stream of nitrogen and subjected to electrospray 
mass spectrometric analysis (28). 
Bio-5ʹ-AMP synthesis assays.  
The assays contained 50 mM Tris-HCl buffer (pH 8.0), 5.5 mM MgCl2, 100 mM 
KCl, 0.1 mM TCEP, 10 µM ATP, 25 µM biotin, 2.5 µM BirA, 0.1 µM [α-32P]ATP and 
with or without 50 µM AccB-86, PyC-77, or BLAP for a total reaction mixture of 20 µl 
(25, 26). The reaction mixtures were incubated at room temperature for 30 min. A portion 
of each reaction mixture (1 µl) was spotted on cellulose thin-layer chromatography (TLC) 
plates and developed in isobutyric acid-NH4OH-water (66:1:33) (75). The thin-layer 
chromatograms were dried for 10 h and exposed to a phosphorimaging screen and 
visualized using a Fujifilm FLA-3000 Phosphor Imager and Fujifilm Image Gauge 
software.  
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β-Galactosidase assays.  
Cultures were grown overnight in defined medium containing 1.6 nM biotin. The 
cultures were diluted to an OD595 of 0.2 in defined media containing various 
concentrations of biotin (1.6, 4, 20, 40, 80, 400 nM, 4 µM) and grown to OD595 of 0.8 and 
induced with 1 mM IPTG for an additional 2 h. β-Galactosidase activity was determined 
as described by Harwood and Cutting for Bacillus following permeabilization with 
lysozyme (51).  
 
Results 
B. subtilis BirA is a Group II BPL that binds three operator sites.  
To test the relative affinities of the predicted B. subtilis BirA binding sites we 
purified the protein (Figure 2.2) and performed electrophoretic mobility shift assays 
(EMSAs) on DNA fragments containing the three sites (Figure 2.3A). Full dependence of 
binding on ATP and biotin required treatment of the protein with neutral hydroxylamine 
to remove Bio-5′-AMP accumulated in the active site during expression in E. coli. With 
the treated BirA binding of the biotin biosynthetic operator (bioO) was observed only in 
the presence of both biotin and ATP (Figure 2.3B). BirA also bound the yhfU and yuiG 
operators only in the presence of biotin and ATP (Figure 2.3C, 2.3D). Although the three 
binding sites have slightly different DNA sequences (Figure 2.3A), analysis of binding 
over a range of BirA concentrations showed that the three sites had very similar binding 
affinities (Figure 2.3E). B. subtilis BirA failed to show non-specific DNA binding (Figure 
2.3F) as assayed by use of a fragment from the coding sequence of the yngHB gene. BirA 
preparations that had not undergone hydroxylamine treatment showed some interaction 
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with bioO in the absence of biotin and ATP (Figure 2.3G). BirA did not interact with a 
site that was composed of only one of the B. subtilis bioO inverted repeats suggesting that 
the form of BirA active in DNA binding is a dimer (Figure 2.3H). B. subtilis BirA 
interacted only very weakly with the E. coli bioO DNA site (Fig 2.3I). 
B. subtilis BirA biotinylates three cognate proteins and the reactions proceed via Bio-5′-
AMP.  
Each of the acceptor proteins, AccB-86, PyC-77 and BLAP (Figure 2.4A), was 
purified after high-level expression in E. coli (Figure 2.2). In the first two cases the N-
terminal halves of the proteins were deleted to avoid protein aggregation during 
purification (the deleted segments are responsible for interaction with other proteins of 
the enzyme complexes and play no role in biotinylation). Electrospray ionization mass 
spectrometry results matched the theoretical masses of the apo forms of the three proteins 
and showed that the preparations were free of the biotinylated forms (Figure 2.4B). When 
the apo forms of AccB-86, PyC-77 and BLAP were incubated with ATP, biotin and 
purified B. subtilis BirA and subsequently analyzed by mass spectrometry, mass values 
very similar to the theoretical values for biotinylated forms of all three acceptor protein 
were obtained (Figure 2.4B). In the presence of α-32P-labeled ATP and biotin B. subtilis 
BirA formed labeled Bio-5′-AMP. Upon addition of any of the three acceptor proteins 
(AccB-86, PyC-77, or BLAP) the Bio-5′-AMP intermediate was no longer detected and 
AMP accumulated which indicated transfer of biotin to each of the acceptor proteins 
(Figure 2.4C). In conclusion, we have experimentally verified the bioinformatic analyses 
of the genes regulated by B. subtilis BirA and the proteins modified by its ligase activity. 
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B. subtilis BirA does not require the N-terminal DNA binding domain for normal ligase 
activity. 
The in vitro data presented above indicate that B. subtilis BirA behaves in a 
manner that strongly parallels that of E. coli BirA despite the low sequence similarity of 
the two proteins. However, E. coli BirA has recently been shown to undergo extensive 
inter-domain communication that is required for full ligase activity (25). These 
observations confirm and extend those of Xu and Beckett (100) and demonstrate that the 
E. coli BirA N-terminal domain plays a role in organizing the active site of BirA (25). 
Specifically, the wing of the winged HTH structure interacts with the ligase active site 
biotin binding loop and acts to organize the active site to give high affinity binding of 
biotin and Bio-5′-AMP (25). 
To determine if another Group II BPL, that of B. subtilis, requires such 
communication of the catalytic and N-terminal domains for full ligase activity, we 
constructed genes encoding several N-terminal B. subtilis BirA deletion proteins. The 
deletion endpoints were based on structural modeling of B. subtilis BirA based on the 
crystal structure of S. aureus BirA (PDB 4DQ2) (71) (Figure 2.5). BirA deletions Δ2-63 
and Δ2-65 eliminated the predicted N-terminal domain whereas BirA deletions Δ2-74 
and Δ1-81 also cut into the predicted central catalytic domain. Complementation assays 
using the E. coli birA1 mutant strain BM4092 and the E. coli ∆birA deletion strain 
VC618 were used to test the ligase activities of the B. subtilis BirA N-terminally deleted 
proteins. These assays showed that upon expression of the B. subtilis Δ2-63 BirA, Δ2-65 
BirA and wild type proteins in strain BM4092 all three BPLs supported growth equally 
well on medium containing 1.6 nM biotin (the minimal level allowing growth of E. coli) 
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(Figure 2.6A). These results indicated that the ligase activities of these two deletion 
proteins were essentially normal. In contrast, upon expression of the E. coli BirA lacking 
its amino terminus (Δ2-65 BirA), growth of the transformed strain required a biotin 
concentration that was 1000-fold greater. The complementation activities of the other two 
B. subtilis deletion proteins, BirA Δ2-74 and BirA Δ1-81 were either partially (BirA Δ2-
74) or totally (BirA Δ1-81) compromised (Figure 2.6A). To ensure that residual activity 
of the host BirA1 protein did not play a role in growth restoration we also performed 
complementation of the ∆birA E. coli strain VC618 and obtained a similar 
complementation pattern (Figure 2.6B). 
 The ligase activities of the purified B. subtilis BirA N-terminal deletion proteins 
(Figure 2.2) were also tested by in vitro biotinylation assays. As expected from the 
complementation results the Δ2-63 and Δ2-65 BirA proteins showed Bio-5′-AMP 
synthesis and biotin transfer activities indistinguishable from those of the wild type 
protein (Figure 2.7). In contrast the Bio-5′-AMP synthetic abilities of the Δ2-74 and Δ1-
81 BirAs were significantly reduced relative to wild type BirA. However, the biotin 
transfer activity of the Δ2-74 BirA was comparable to wild type levels. Biotin transfer by 
the Δ1-81 BirA was significantly reduced compared to the wild type protein (Figure 2.7). 
In agreement with prior work (25, 100) the E. coli Δ2-65 BirA was significantly reduced 
in Bio-5′-AMP synthesis and in biotin transfer (Figure 2.7). 
Bacillus subtilis BirA dimerizes in the presence of biotin and ATP.  
Dimerization is required for DNA binding of E. coli BirA and dimerization is 
dependent on biotin and ATP binding. To determine the oligomerization state of B. 
subtilis BirA, purified BirA was incubated with EGS in the presence or absence of biotin 
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and ATP. Chemical crosslinking indicated that BirA forms a dimer only in the presence 
of both biotin and ATP (Figure 2.8A). Dimerization was also observed for the N-
terminally truncated ∆2-65 BirA (Figure 2.8B). Note that the characterized Group I BPLs 
can either be dimeric as is the Pyrococcus horikoshii protein (7, 40) or monomeric as are 
the Mycobacterium tuberculosis (76), Aquifex aeolicus (94) and Propionibacterium	
freudenreichii	subsp.	shermanii (84) BPLs. 
Bacillus subtilis BirA follows the E. coli BirA regulatory model.  
In E. coli regulation of the biotin biosynthetic gene transcription depends not only 
on the concentration of biotin but also the levels of unbiotinylated AccB (1, 38, 87). This 
is an important attribute because biotin is only active in central metabolism when it is 
protein bound. Hence, the rate of biotin operon transcription is sensitive not only to the 
intracellular concentration of biotin, but also to the supply of the proteins to which the 
biotin must be attached. Moreover, accumulation of the unmodified protein increases the 
rate of biotin synthesis thus ensuring replacement of the biotin consumed in protein 
modification. 
To determine if this regulatory facet also applies to another Group II BPL, we 
constructed a B. subtilis strain that could be used to monitor regulation of biotin operon 
transcription upon alteration of the levels of the AccB-86 acceptor protein. This strain 
contains the bioB141 mutation rendering it a biotin auxotroph, a bioW-lacZ 
transcriptional fusion and an ectopic IPTG-inducible gene encoding AccB-86. This strain 
was grown in chemically defined media containing various concentrations of biotin. 
Upon induction of AccB-86 expression with IPTG β-galactosidase assays showed that  
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expression of the biotin operon was dereprepressed at biotin concentrations that normally 
cause repression (Figure 2.9) in a manner similar to that seen in E. coli (1, 38, 87). 
 
Discussion 
B. subtilis BirA complements the ligase activity of E. coli BirA mutant strain 
BM4092, but fails to complement the regulatory function of E. coli BirA. This latter 
result is not surprising since E. coli and B. subtilis BirAs bind different operator 
sequences and have different spacing of the palindromic elements. We have shown that 
B. subtilis BirA is a Group II BPL that binds equally well to the three operators predicted 
by others (Figure 2.3). Binding is observed only in the presence of both biotin and ATP 
indicating that Bio-5′-AMP is the regulatory ligand. Interestingly, EMSA showed that B. 
subtilis BirA weakly binds E. coli bioO (Figure 2.3I), suggesting some distant 
relationship between the operators. Similar to E. coli, dimerization of B. subtilis BirA 
occurs only in the presence of biotin and ATP, a further indication that Bio-5′-AMP is the 
regulatory ligand (Figure 2.8A). The B. subtilis Δ2-65 BirA also formed dimers 
indicating that the N-terminal domain is not required for dimerization (Figure 2.8B).  
 Deletions of the N-terminal DNA binding domain of E. coli BirA result in 
proteins having only very weak ligase activities indicating inter-domain interactions are 
required for full ligase activity (25, 100). These interactions have been shown to occur 
between the wing of the winged HTH domain and the biotin-binding loop of the catalytic 
domain. Deletion of only the fourteen-residue wing has as drastic an effect as deletion of 
the entire N-terminal domain, but was largely restored by insertion of a foreign wing of 
	 36	
similar structure (25). Moreover, a mutation within the wing can restore function to 
proteins having mutant biotin binding loops (25). 
Although the HTH domain of our modeled B. subtilis BirA structure includes a 
wing, the structure is not required for full ligase activity. Both the Δ2-63 and Δ2-65 
BirAs lack the entire N-terminal domain but performed the ligase partial reactions as well 
as the wild type protein both in vivo and in vitro (Figure 2.7). Deletions that entered the 
predicted catalytic core of the protein resulted in either compromised (Δ2-74 BirA) or 
highly defective (Δ1-81 BirA) proteins (Figure 2.7). The Bio-5′-AMP synthetic ability of 
the Δ2-74 BirA was significantly decreased, although the protein transferred the biotin 
moiety normally suggesting that the putative α-helix near residue 74 may be involved in 
stabilizing biotin and ATP or Bio-5′-AMP binding. Although B. subtilis Δ1-81 BirA 
failed to replace the E. coli ligase in vivo (Figure 2.6), it retained weak Bio-5′-AMP 
synthesis and biotin transfer activities (Figure 2.7) suggesting that the loop predicted near 
residue 81 is required for efficient binding of biotin and ATP. These data indicate that 
unlike E. coli, B. subtilis BirA does not require an intact N-terminal DNA binding 
domain for full ligase activity. Instead, the first α-helix and loop of the modeled central 
domain seem to be important in binding biotin and ATP. 
E. coli BirA is a highly dynamic protein as shown both by physical (91, 92, 99) 
and mutational (26) analyses. In the latter case mutations in the catalytic and C-terminal 
domains as well as in the HTH domain can result in super-repressor phenotypes. These 
proteins are BirAs that repress bio operon expression even at biotin concentrations that 
normally fail to repress transcription. Although E. coli BirA has been studied for over 30 
years (8, 75) and four different crystal structures have been solved, the details of how the 
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protein binds its operator site remain unknown. Despite much effort in several 
laboratories no diffraction grade crystals of the operator DNA with liganded E. coli BirA 
have been obtained. This could be due to competing interactions of the N-terminal 
domain with the catalytic domain and operator giving a mixture of molecular species that 
preclude crystallization. If so, the apparent lack of such interactions in B. subtilis BirA 
may allow crystallization of this protein with its operator DNA. 
 The BLAP protein was biotinylated by B. subtilis BirA in vitro suggesting that 
BLAP may be the biotin carboxyl carrier protein for a biotin-dependent enzyme. The 
genes that neighbor yngHB, the BLAP encoding gene, are annotated as propionyl-CoA 
carboxylase subunits. However, a recent report suggests that these genes may comprise a 
methylcrotonyl-CoA carboxylase involved in leucine degradation (55). 
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Tables 
Table 2.1. Bacterial strains used in this chapter. 
Strain Relevant Genotype or Description 
Reference or 
Derivation 
B. subtilis     
168 trpC2 Lab collection 
1A330 aroG932 bioB141 BGSC 
SKH001 1A330 bioW::lacZ This study 
SKH002 SKH001 amyE:: P spac accB-86 This study 
E. coli      
MG1655 E. coli K-12 wild type Lab collection 
DH5α 
Δ(argF-lacZ)U169 glnV44 Φ80 Δ(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 Lab collection 
BM4092 
[araD139]B/r, Δ(argF-lac)169, λ-, TP(bioF-
lacZ)501, flhD5301, Δ(fruK-yeiR)725(fruA25), 
relA1, rpsL150(strR), rbsR22, birA1, Δ(fimB-
fimE)632(::IS1), deoC1 
Barker and 
Campbell, 
1980 
BL21 λ (DE3) ompT, hsdSB (rB–, mB–), dcm, gal, λ(DE3) Novagen 
VC618 MG1655 Δ lacZY, bioF::lacZY, birA::KmR, pVC18 
Chakravartty 
and Cronan, 
2012 
VC832 BL21 λ (DE3), pVC36  
Chakravartty 
and Cronan, 
2013 
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Table 2.2. Plasmids used in this chapter. 
Plasmid Relevant Genotype or Description Reference or Derivation 
pET19b T7 promoter expression vector, AmpR Novagen 
pSKH001 pET19b encoding N-terminal hexahistidine tagged B. subtilis BirA, AmpR This study 
pET28b T7 promoter expression vector, KanR Novagen 
pSKH003 pET28 encoding accB-86 This study 
pSKH004 pET28 encoding pyc-77 This study 
pQC026 pET28b encoding C-terminal Hexahistidine tagged BLAP [23] 
pBAD322K Medium copy expression vector, KanR [48] 
pSKH005 pBAD322K encoding B. subtilis 64-325 This study 
pSKH006 pBAD322K encoding B. subtilis WT BirA This study 
pSKH007 pBAD322K encoding E. coli BirA 66-321 This study 
pSKH008 pBAD322K encoding E. coli WT BirA This study 
pSKH009 pBAD322K encoding B. subtilis 66-325 This study 
pSKH010 pBAD322K encoding B. subtilis 75-325 This study 
pSKH011 pBAD322K encoding B. subtilis 82-325 This study 
pBAD322Cm Medium copy expression vector, CmR [48] 
pSKH012 pBAD322Cm encoding B. subtilis 64-325 This study 
pSKH013 pBAD322Cm encoding B. subtilis WT BirA This study 
pSKH014 pBAD322Cm encoding E. coli BirA 66-321 This study 
pSKH015 pBAD322Cm encoding E. coli WT BirA This study 
pSKH016 pBAD322Cm encoding B. subtilis 66-325 This study 
pSKH017 pBAD322Cm encoding B. subtilis 75-325 This study 
pSKH018 pBAD322Cm encoding B. subtilis 82-325 This study 
pSKH019 pET19b encoding N-terminal hexahistidine tagged BirA 64-325, AmpR This study 
pSKH020 pET19b encoding N-terminal hexahistidine tagged BirA 66-325, AmpR This study 
pSKH021 pET19b encoding N-terminal hexahistidine tagged BirA 75-325, AmpR This study 
pSKH022 pET19b encoding N-terminal hexahistidine tagged BirA 82-325, AmpR This study 
pMUTIN4 spoVG-lacZ, ermR [49] 
pDR111 SpcR, 5'-amyE, 3'-amyE, phyper-spank G. W. Ordal  
pSKH023 pMUTIN4 encoding B. subtilis bioW internal 500 bp  This study 
pSKH024 pDR111 encoding B. subtilis accB-86 This study 
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Table 2.3. Oligonucleotide primers used in this chapter. 
Oligo-
nucleotide Description Sequence 
SKH001 BirA F NdeI GAGTGGCTGAACATATGCGGTCAAC 
SKH002 BirA stop R Xhol GGCTTGTACCCTCGAGTTAGCCCAATTC 
SKH005 accB F NcoI CCATGGAAAAGCAAGATGAGAATCTGCATAAA 
SKH006 accB stop R XhoI 
CTCGAGCTTACTCCGCTTTTACAAGAAATAGA
GG 
SKH007 pyc F NcoI CCATGGAACGGACAAATCCAAGCCAC 
SKH009 pyc stop R XhoI CTCGAGTTTATGCTTTTTCAATTTCAAGGAGC 
SKH014 bioO F GATCCTTTCTTCTATTGACAGAAAC 
SKH015 bioO R CGC CCTTTCACTGATAACTGAAGAAC 
SKH016 yhfU F ACCATCAAAAACCGGTCTGCCATAC 
SKH017 yhfU R CCAAAAAGTAATCAAATATGGTTATAC 
SKH018 yuiG F ATTGATCGGACTGTCTTGTT 
SKH019 yuiG R CCCTTAGGTTGACATACACA 
SKH026 EC bioO F GATATGGCGTTGGTCAAAGGCAAG 
SKH027 EC bioO R GGGGCTTCTCCAAAACGTGTTTTTTG 
SKH034 bioO half F GAAAAAGACCGTTTTGTGTG 
SKH035 bioO half R ATTCAAAGGTTAACAATTAGAATATATTATTCTCTCCTG 
SKH028 Non 125 F GCATGACGGTTAGCATACAAATGGCAG 
SKH029 Non 125 R AACGATCGGGATTTCCATTTTCATCGATTC 
SKH036 BirA 64-325 EcoRI F 
ACTGCGAATTCACCATGAAACCCGGAAAACT
CAGTGAAAGCG 
SKH037 BirA SalI R ACTGAGTCGACTTAGCCCAATTCGATATCGGCAG 
SKH038 BirA EcoRI F CTGACGAATTCACCATGCGGTCAACATTAAGAAAAGACC 
SKH040 BirA 64-325 NdeI F 
CAGTCCATATGAAACCCGGAAAACTCAGTGA
AAG 
SKH041 BirA BamHI R ACTGGGATCCTTAGCCCAATTCGATATCG 
SKH042 EC BirA 65-321 EcoRI F 
ACTGCGAATTCACCATGCAGTTACTTAATGCT
AAACAGATATTG 
SKH043 EC BirA SalI R CAGTCGTCGACTTATTTTTCTGCACTACGCAG 
SKH044 BirA 82-325 NdeI F 
ACGTACATATGGGCCAGCATCTTATTTACCAT
G 
SKH045 BirA 82-325 EcoRI F 
AGCTAGAATTCACCATGGGCCAGCATCTTATT
TAC 
	 41	
Table 2.3. (cont.) 
SKH046 BirA 66-325 EcoRI F 
ACTGCGAATTCACCATGGGAAAACTCAGTGA
AAGCG 
SKH047 BirA 66-325 NdeI F CAGTCCATATGGGAAAACTCAGTGAAAGCG 
SKH048 BirA 75-325 EcoRI F 
ACTGCGAATTCACCATGTTTGGATTAAAAACG
GAAG 
SKH049 EC BirA EcoRI F 
ACTGGAATTCACCATGAAGGATAACACCGTG
CCAC 
SKH050 BirA 75-325 NdeI F CAGTCCATATGTTTGGATTAAAAACGGAAG 
SKH057 bioW 500 F ACGTGAATTCCATACAGTCAATGCTTTATTAG 
SKH058 bioW 500 R GACTGGATCCCTTACCCGCAACATAGCCTG 
SKH065 ycgB F CTTACAGAAGAGCGGTAAAAGAAGAAATAAAAAAG 
SKH066 lacI R CCGTCTCACTGGTGAAAAGAAAAAC 
SKH067 ldH R CATTGCTTTTTCTTTATTTACATCAATGACCACAA 
SKH069  RBS accb-86 F  ACGGTCGACAAGGAGGAAAAAATATGGAAGCACCAAAGCAAGATG 
SKH070 accb-86 R GACGCATGCTTACTCCGCTTTTACAAGAAATAGAGGTTGTC 
SKH073 pDR111 F Seq CTCGAGGGTAAATGTGAGCACTCAC 
SKH074 pDR111 R Seq GAAAGTATTACATATGTAAGATTTAAATGCAACCG 
SKH075 specR F TGAATCTTCTCCATTAGAACATAGGGAGAG 
MM1 5' BioW F CGATCCTTTCTTCTATTGACAGAAACAGG 
MM2 LacZ R GGTGTAGATGGGCGCATCGTAAC 
MM3 pSPAC F CTACACAGCCCAGTCCAGACTATTCGG 
MM4 3' BioW R ATGGCGTCATCTAGTTCTTTTTTGCGG 
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Figures 
 
Figure 2.1. Sequence alignments of S. aureus BirA, B. subtilis BirA and E. coli BirA. 
B. subtilis BirA has 31% amino acid identity to S. aureus BirA and 27% amino acid 
identity to E. coli BirA. Conserved residues are in white text and highlighted in red and 
similar residues are in red text and boxed in blue. The S. aureus BirA secondary structure 
(PDB: 4DQ2) (71) is shown above the amino acid sequence. 
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Figure 2.2. Purification of the wild type and N-terminal deletion BirA proteins and 
the biotin acceptor proteins. The proteins were purified as described in Experimental 
Procedures and subjected to SDS-electrophoresis on a 4-20% polyacrylamide gel (from 
BioRad). M: molecular weight strandards (Precision Plus Protein Standard Kaleidoscope 
from BioRad). Lane 1: B. subtilis N-terminally hexahistidine-tagged BirA (38.9 kDa). 
Lanes 2-5. B. subtilis N-terminally hexahistidine-tagged Δ2-63 BirA (31.8 kDa), Δ2-65 
BirA (31.6 kDa), Δ2-74 BirA (30.4 kDa) and Δ1-81 BirA (29.7 kDa), respectively. Lanes 
6-11 are the B. subtilis acceptor proteins AccB-86 (9.4 kDa), PyC-77 (8.3 kDa) and biotin 
lipoyl attachment protein (BLAP) (8.73 kDa). Lane 10 is E. coli C-terminal 
hexahistidine-tagged BirA. Lane 11 is E. coli C-terminal hexahistidine tagged Δ2-65 
BirA (29.18 kDa) and lane 11 is E. coli AccB-87. 
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Figure 2.3. Sequence alignments of B. subtilis BirA DNA binding sites and 
electrophoretic mobility shift assay of DNA binding by BirA. A. B. subtilis has three 
predicted BirA DNA binding sites: 5’ UTR of the bioWAFDBI operon, 5’ UTR of yuiG,  
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Figure 2.3. (cont.) 
and 5’ UTR of the yhfUTS operon. Conserved residues are highlighted in red and similar 
residues are highlighted in yellow. B.-D. B. subtilis BirA binding to bioO, the yuiG 
operator and the yhfU operator, respectively. Note that only in the presence of biotin and 
ATP is binding observed. E. Quantitation of DNA binding by BirA (Quantity One 
software). The results show the average of three independent experiments, and the error 
bars denote standard error of the mean. F. BirA binding to non-operator DNA (a 125 bp 
internal fragment of the yngHB gene that encodes BLAP). G. BirA binding to bioO 
without hydroxylamine treatment. Bio-5′-AMP accumulates in the active site during 
expression in E. coli and survives purification of BirA. H. B. subtilis BirA binding to a 
half site of the inverted repeat of B. subtilis bioO. Note lane 2 is positive control full-
length bioO. I. B. subtilis BirA binding to E. coli bioO. A collection of all putative BirA 
binding sites in diverse bacteria can be found in the RegPrecise database 
(http://regprecise.lbl.gov/RegPrecise/). 	  
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Figure 2.4. In vitro biotinylation of the B. subtilis biotin acceptor proteins. A. 
Sequence alignment of the B. subtilis biotinylated proteins. Conserved residues are in 
white text and highlighted in red and similar residues are in red text and boxed in blue. 
The black arrow indicates the conserved lysine residue that becomes biotinylated. B. 
Mass spectrometry values for purified acceptor proteins AccB-86, PyC-77, and BLAP. C. 
Thin layer chromatographic analysis of B. subtilis BirA ligase reaction: synthesis of Bio-
5′-AMP and transfer of biotin to AccB-86, PyC-77, and BLAP.   
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Figure 2.5. B. subtilis BirA modeled using the S. aureus BirA crystal structure (PDB 
4DQ2) (71) as template. The UCSF Chimera package (74) was used to create the image. 
Residues corresponding to the N-terminal deletion end points are given. The domains of 
the modeled protein are indicated.  
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Figure 2.6. Complementation of E. coli strains by expression of the BirA N-terminal 
deletion proteins. A. Complementation of E. coli BirA mutant strain BM4092. B. 
Complementation of E. coli ΔbirA strain VC618. Strains were grown on M9 minimal 
medium containing different biotin concentrations (1.6 nM, 4.1 nM, 41 nM and 1.6 µM) 
and X-gal. The blue color indicates transcription of bioF-lacZ fusion. The white colonies 
indicate transcriptional repression of the biotin operon by BirA binding at bioO. Note that 
B. subtilis wild type BirA does not complement the regulatory function of E. coli BirA 
and thus gives blue colonies. 
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Figure 2.7. In vitro biotinylation analyses of the BirA N-terminal deletion proteins. 
A. Thin layer chromatographic analysis of wild type B. subtilis BirA and B. subtilis BirA 
N-terminal deletions with and without the addition of acceptor protein AccB-86. The B.  
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Figure 2.7. (cont.) 
subtilis wild type BirA and the B. subtilis Δ2-63, Δ2-65, Δ2-74 and Δ1-81 BirA deletion 
proteins were assayed as given on the figure. B. Quantitation of Bio-5′-AMP synthesis by 
wild type B. subtilis BirA and the B. subtilis BirA N-terminal deletion proteins. The 
results show the average of three independent experiments, and the error bars denote 
standard error of the mean. C. Quantitation of biotin transfer to AccB-86 by wild type B. 
subtilis BirA and B. subtilis BirA N-terminal deletions. The results show the average of 
three independent experiments, and the error bars denote standard error of the mean. D. 
Thin layer chromatographic analysis of wild type E. coli BirA, E. coli Δ2-65 BirA, wild 
type B. subtilis BirA, and B. subtilis Δ2-65 BirA. E. Quantitation of Bio-5′-AMP 
synthesis by wild type E. coli BirA, E. coli Δ2-65 BirA, wild type B. subtilis BirA, and B. 
subtilis Δ2-65 BirA. The results show the average of three independent experiments, and 
the error bars denote standard error of the mean. F. Quantitation of biotin transfer to E. 
coli AccB-87 or B. subtilis AccB-86 by wild type E. coli BirA, E. coli Δ2-65 BirA, wild 
type B. subtilis BirA and B. subtilis Δ2-65 BirA. The results show the average of three 
independent experiments, and the error bars denote standard error of the mean.  	  
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Figure 2.8. Chemical crosslinking of the B. subtilis wild type and Δ2-65 BirA 
proteins. A. Wild type BirA. B. The Δ2-65 BirA. Note that efficient dimer formation 
requires the presence of both biotin and ATP. The EGS concentrations are given in mM. 	  
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Figure 2.9. β-Galactosidase assays of the effect of AccB-86 levels on bioO-dependent 
transcription. The bioW::lacZ spac accB-86 strain SKH002 was grown in defined 
medium supplemented with the indicated concentrations of biotin plus or minus addition 
of IPTG to induce synthesis of the AccB-86 acceptor protein. The results are the average 
of three independent experiments and the error bars denote standard error of the mean.  
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Chapter 3 
The Staphylococcus aureus Group II Biotin Protein Ligase BirA is an Effective 
Regulator of Biotin Operon Transcription and Requires the DNA Binding Domain 
for Full Enzymatic Activity2 
 
Introduction 
Biotin protein ligase (BPL) is an essential enzyme that catalyzes covalent 
attachment of biotin to biotin dependent enzymes in a two step reaction (Figure 3.1A). In 
the first half reaction, BPL binds both biotin and ATP to synthesize biotinoyl-AMP (Bio-
AMP) and pyrophosphate. The mixed anhydride bond of Bio-AMP then undergoes 
nucleophilic attack by the ε-amino group of the conserved lysine residue of the acceptor 
protein resulting in covalently attached biotin and free AMP (Figure 3.1A). Microbial 
BPLs are classified into two groups. Both Group I and Group II BPLs have well 
conserved catalytic cores and C-terminal domains. Group II BPLs (generally called 
BirAs) are classified based on the presence of an N-terminal helix-turn-helix DNA 
binding domain that is lacking in the Group I enzymes. The E. coli BirA is the best 
studied example of how an enzyme can also act as a transcriptional regulator of the biotin 
biosynthetic operon (12, 34). Transcriptional repression of the E. coli biotin operon 
occurs when biotin acceptor proteins have been fully biotinylated thereby allowing BirA 
to accumulate Bio-AMP in its active site. The presence of Bio-AMP results in BirA 
dimerization and subsequent DNA binding that represses transcription of the biotin 
biosynthetic operon (Figure 3.1B). Derepression of the biotin operon transcription occurs 
upon increased levels of unmodified biotin acceptor proteins (Figure 3.1D) (1, 38, 87) or 																																																								
2 This chapter was published in Molecular Microbiology (2016) 102(3):417-429. 
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low biotin levels (9) (Figure 3.1C). Transfer of accumulated Bio-AMP to acceptor 
proteins results in monomeric BirA which is unable to bind the biotin operator. The BirA 
of the distantly related bacterium Bacillus subtilis closely follows the E. coli 
transcriptional regulation model (17, 54). 
The putative S. aureus BirA contains an N-terminal winged helix-turn-helix DNA 
binding domain. However, the protein was recently reported to dimerize in the absence of 
either biotin or Bio-AMP with a Kd of 29 µM (85), a concentration much lower than 
analogous preparations of E. coli BirA (90). Moreover, it was reported that S. aureus 
BirA bound the operator sequence in the absence of biotin and Bio-AMP leading to a 
question of the biological function of the protein. The reported electrophoretic mobility 
shift assays (EMSAs) showed that the unliganded S. aureus BirA bound the operator 
DNA with only a 6-fold lower affinity than the protein that bound the Bio-AMP 
regulatory ligand (Kd of 649 ± 43 nM vs. Kd of 108 ± 6 nM) (85). This high level of 
DNA binding activity in the absence of biotin or Bio-AMP should preclude S. aureus 
BirA from being an effective regulator of biotin operon transcription since DNA binding 
would occur without regard for the cellular levels of biotin and Bio-AMP. Thus, even if 
the cellular concentration of biotin was low and engenders a requirement for biotin 
biosynthesis (and/or biotin transport), operator binding would result in transcriptional 
repression of the biotin biosynthesis operon (and of the biotin transporter, bioY). 
Therefore, the S. aureus BirA would hinder rather than expedite cellular responses to 
biotin deficiency. To test whether or not the S. aureus BirA had this seemingly perverse 
activity, we utilized the fact that the S. aureus BirA DNA binding sites bioO and bioY are 
very similar to that of the previously studied B. subtilis bioO operator (Figure 3.3A). We 
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replaced the well-characterized B. subtilis birA gene (17, 54) with that encoding the S. 
aureus BirA and assayed regulation by the levels of biotin and acceptor protein. Since 
these experiments indicated that the S. aureus BirA was an efficient regulator in vivo, we 
reconsidered the EMSA results and utilized fluorescence anisotropy to test DNA binding 
in free solution. 
Finally we tested the role of the S. aureus BirA DNA binding domain in the 
enzymatic activity of the protein. We expected that, like the B. subtilis protein (54), 
deletion of the N-terminal domain would not affect ligase activity. To our surprise 
deletion of the DNA binding domain resulted in severely decreased ligation activity as 
was previously observed with E. coli BirA (25, 100).  
 
Materials and Methods 
Strains, plasmids, chemicals and culture media.  
All B. subtilis strains were derivatives of strain 168 whereas the E. coli strains 
were derivatives of strains B and K-12 (Table 3.1). The plasmids used and constructed 
are given in (Table 3.2). The rich medium for growth of E. coli and B. subtilis was LB 
broth. The defined medium for E. coli was M9 salts supplemented with 0.5% glucose or 
0.5% glycerol and 0.01% vitamin-free Casamino Acids (Difco) whereas the defined 
medium for B. subtilis was Spizizen salts supplemented with 0.5% glycerol and 0.05% 
vitamin-free Casamino Acids (Difco) plus 0.01% each of tryptophan, tyrosine, isoleucine 
and phenylalanine. Antibiotics were used at the following concentrations (in µg/ml): 
kanamycin sulfate, 50; chloramphenicol, 25; erythromycin sulfate, 1; lincomycin, 12.5 
and spectinomycin, 100. Oligonucleotides were purchased from Integrated DNA 
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Technologies. PCR amplification was performed using Phusion high fidelity DNA 
polymerase (New England BioLabs) according to manufacturer protocols. DNA 
constructs were sequenced by ACGT, Inc. Reagents and chemicals were obtained from 
Sigma-Aldrich and Fisher, unless otherwise noted. New England BioLabs supplied 
restriction enzymes and T4 DNA ligase. Life Technologies provided SYBER Green I 
Nucleic Acid Gel stain and the 6% DNA Retardation Novex TBE Gels. 
Plasmid constructions.  
The S. aureus birA gene was amplified by PCR from S. aureus strain Newman 
genomic DNA with primers SKH076 and SKH077 (Supporting information Table S3) 
that contained PciI and XhoI sites. The product was digested with PciI and XhoI and 
ligated into the NcoI and XhoI sites of pET28b resulting in plasmid pSKH025 that 
encoded the protein with a C-terminal hexahistidine tag.  
The 500 bp immediately downstream of B. subtilis birA was PCR amplified from 
B. subtilis strain 168 genomic DNA using primers SKH102 and SKH103 (Supporting 
information Table S3) that, respectively, contained SalI and XhoI sites. The product was 
digested with SalI and XhoI and ligated into plasmid pDG780 digested with the same 
enzymes to give pDG780-panB. The last 500 base pairs of B. subtilis cca was PCR 
amplified from B. subtilis strain 168 genomic DNA with primers SKH104 and SKH105 
(Supporting information Table S3) that contained a BamHI site and an overlapping S. 
aureus birA sequence, respectively. S. aureus birA was PCR amplified from S. aureus 
strain Newman genomic DNA with primers SKH106 that contained the B. subtilis cca 
overlap and SKH107 that contained an EcoRI site. The last 500 base pairs of B. subtilis 
cca and S. aureus birA were assembled by overlap PCR using primers SKH104 and 
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SKH107 (Table 3.3). The product was digested with BamHI and EcoRI and ligated into 
pDG780-panB digested with the same enzymes to give pSKH031.  
The plasmids encoding the SaBirA N-terminal domain deletions were constructed 
as follows. S. aureus wild type birA, Δ2-65 birA, Δ2-74 birA, and Δ2-81 birA constructs 
were amplified by PCR from S. aureus strain Newman genomic DNA using forward 
primers SKH076, SKH078, SKH079, SKH080, respectively, plus reverse primer 
SKH081. The primers contained PciI and SalI sites, respectively. The products were 
digested with PciI and SalI and ligated into the NcoI and SalI sites of pBAD322Cm, to 
give pSKH026, pSKH027, pSKH028, and pSKH029 respectively.  S. aureus Δ48-63 birA 
was amplified by PCR from S. aureus strain Newman genomic DNA with forward primer 
SKH076 containing a PciI site and reverse primer SKH097 which contained an 
overlapping sequence and forward primer SKH098 which contained the complement of 
the SKH097 overlap and reverse primer SKH080 containing a SalI site. The two 
fragments were fused by overlap extension PCR using primers SKH076 and SKH080 
(Table 3.3). The product was digested with PciI and SalI and ligated into the NcoI and 
SalI sites of pBAD322Cm, to give pSKH030. 
Bacillus subtilis strain constructions.  
B. subtilis competent cell preparation and transformation were carried out as 
described by Dubnau and Davidoff-Abelson (41). Strains SKH001 and SKH002 were 
transformed with either linearized pSKH026 to replace the B. subtilis birA with S. aureus 
birA with a kanamycin cassette to give strains SKH003 and SKH004, respectively. The 
integration event was verified by PCR and sequencing of the PCR product with primers 
SKH134 and SKH135. 
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Purification of S. aureus BirA.  
E. coli BL21 Star (DE3) was transformed with pSKH025. The strain was grown 
at 37°C in LB medium supplemented with kanamycin to an OD600 of 0.8 and expression 
was induced by addition of IPTG to 1 mM. Following growth for an additional 12 h at 
30°C the cells were recovered by centrifugation and suspended in lysis buffer. Lysis 
buffer was 50 mM HEPES, 250 mM NaCl, 0.1 mM tris(2-carboxyethyl)phosphine 
(TCEP), 10 mM imidazole and 5% glycerol (pH 7.5). The cells were lysed by passage 
through a French pressure cell and the lysate was centrifuged to remove unbroken cells 
and cellular debris and the supernatant was added to Ni NTA beads (Qiagen) and 
incubated for 30 min before adding to a disposable 10 ml polypropylene column. The 
column was washed with three column volumes of wash buffer (lysis buffer containing 
60 mM imidazole). BirA was eluted in 1 ml fractions with elution buffer (lysis buffer 
containing 250 mM imidazole). The fractions were analyzed by SDS-PAGE to determine 
purity. Pure fractions were combined and dialyzed against storage buffer (lysis buffer 
lacking imidazole). Aliquots were flash frozen and stored at -80°C. The SaBirA and 
SaBirA(ATP) samples were prepared by incubation of a 1:1 molar ratio of ATP and 
protein plus 1 mM MgCl2 to convert biotin to biotinoyl-AMP. The SaBirA(btn) sample 
was prepared by incubating purified protein with a 1:1 molar ratio of biotin and 1 mM 
MgCl2 to ensure any ATP in the solution would be converted to biotinoyl-AMP and 
could be removed by treatment with 0.2 M neutral hydroxylamine followed by dialysis 
against storage buffer. SaBirA was also prepared by incubating the as purified protein 
with a 5-fold molar excess of purified B. subtilis AccB-86 plus a 2-fold molar excess of 
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ATP and 1 mM MgCl2. The protein was then purified using Qiagen Ni-NTA spin 
columns. Purification of B. subtilis AccB-86 was performed as previously described (54). 
Electrophoretic Mobility Shift Assay (EMSA) of DNA binding.  
The B. subtilis BirA DNA binding site upstream of bioO was PCR amplified from 
B. subtilis 168 genomic DNA with primers SKH014 and SKH015. Negative control DNA 
(blap) was amplified from B. subtilis 168 genomic DNA with primers SKH028 and 
SKH029. The S. aureus BirA binding site upstream of bioO was PCR amplified from S. 
aureus strain Newman genomic DNA with primers SKH099 and SKH100. All DNA 
fragments were 125 bp in length. The PCR products were sized on a 1.8% agarose gel 
and purified using a QIAquick PCR Purification Kit (Qiagen). DNA concentrations were 
determined at OD260 by using a NanoDrop 2000c. The DNA binding reaction contained 
50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 50 mM NaCl, 10% glycerol, 40 nM DNA, the 
indicated concentrations of BirA, 1 mM ATP, 1 mM MgCl2, and 1 µM biotin or were 
modified to the solution conditions used by Soares da Costa and coworkers (85). These 
were 50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 10% glycerol, 40 nM DNA, indicated 
concentrations of BirA, 5 µM ATP, 1 mM MgCl2, and 5 µM biotin (Figure 3.6D). The 
binding reactions were incubated at room temperature for 30 min and then loaded into a 
6% DNA retardation gel. The gel was run in 0.5X TBE buffer at 100 V for 1 hour and 25 
min. The gel was stained with SYBR Green I nucleic acid gel stain and visualized using 
Bio-Rad Chemidoc XRS and Quantity One software. 
Thin layer chromotographic biotinylation assay.  
The in vitro biotinylation assays were performed as previously reported (54). 
Reactions contained 50 mM Tris-HCl buffer (pH 8.0), 5.5 mM MgCl2, 100 mM KCl, 0.1 
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mM TCEP, 10 µM ATP, 25 µM biotin, 2.5 µM BirA, 0.1 µM [α-32P] ATP and with or 
without 50 µM AccB-86 for a total reaction mixture of 20 µl. The reaction mixtures were 
incubated at room temperature for 30 min. A portion of each reaction mixture (1 µl) was 
spotted on cellulose thin-layer chromatography (TLC) plates and developed in isobutyric 
acid-NH4OH-water (66:1:33) (75). The thin-layer chromatograms were dried for 10 h and 
exposed to a phosphorimaging screen and visualized using a Fujifilm FLA-3000 
Phosphor Imager and Fujifilm Image Gauge software. 
β-Galactosidase assays.  
SKH003 was grown overnight in defined media containing 1.6 nM biotin, 
kanamycin, erythromycin and lincomycin. SKH004 was grown overnight in defined 
media containing 1.6 nM biotin, kanamycin, erythromycin with lincomycin, and 
spectinomycin. Cultures were diluted to OD595 of 0.2 in defined media containing various 
concentrations of biotin (4, 20, 40, 80, 400 nM) and grown to an OD595 of 0.8 and then 
induced with 1 mM IPTG for an additional 2 h. β-Galactosidase activity was determined 
as described by Harwood and Cutting (51) following permeabilization of the cells with 
lysozyme.  
Biotin bioassays.  
E. coli strain NRD25 (31) was grown overnight in defined media supplemented 
with chloramphenicol and 1 nM biotin. The cells were recovered by centrifugation at 
15,000xg for 5 min and washed 4 times with 1 ml of M9 medium. The cells were re-
suspended in 1 ml of glucose M9 medium and sub-cultured into 100 ml of glucose M9 
minimal media lacking biotin and containing 5 units of avidin. These cultures were 
incubated at 37°C for 5 h, centrifuged at 15,000xg for 5 min and the cell, pellets washed 
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5 times with 1 ml of M9 medium. The cells were then suspended in 1 ml M9 and added 
to 150 ml of minimal media agar containing the redox indicator 2,3,5-triphenyl 
tetrazolium chloride (0.1%, w/v) (64). Six ml of the agar mixture was added to sectored 
petri dishes. A sterile 6 mm paper disc was applied to the top of the agar and spotted with 
10 µl of biotin standards or denatured protein samples. Protein samples were denatured 
by heating to 99°C for 20 minutes and centrifuged at 15,000xg for 5 min. The supernatant 
was collected and used to spot the paper discs. The pmol indicated were calculated using 
the protein concentrations before denaturation. The plates were incubated at 30°C 
overnight. Growth of strain NRD25 was visualized as a deposit of red formazan. 
Assay of DNA binding by fluorescence anisotropy.  
The sense strand of the 33 base pair S. aureus BirA binding site upstream of bioO 
was synthesized by IDT to include a 5’-fluorescein-label. The labeled sense strand 
(SKH162) and unlabeled antisense strand (SKH163) oligonucleotides were suspended in 
annealing buffer (10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2 and 1 mM DTT) and 
annealed by mixing 1:1 molar ratio and heating to 95°C for 5 minutes and slowly cooled. 
The annealed DNA was purified by PAGE to remove any single stranded DNA. The 
DNA concentration was determined at OD260 by using a NanoDrop 2000c. DNA binding 
reactions contained 50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 10% glycerol, 2 nM DNA, 
and various concentrations of BirA (10 nM to 40 µM). The SaBirA(btn) samples 
contained 200 µM biotin, SaBirA(ATP) samples contained 400 µM ATP and 1 mM 
MgCl2 and the BirA(Bio-AMP) samples contained 200 µM biotin, 200 µM ATP and 1 
mM MgCl2. Buffer containing the fluorescein-labeled DNA was added to a black 96 well 
microplate (Molecular Devices). The indicated amount of a BirA sample was added to 
	 62	
the wells in a final reaction volume of 20 µl. Reactions were incubated at room 
temperature for 30 minutes. Anisotropy values were measured using the fluorescence 
polarization function of the Analyst HT Plate Reader (Molecular Devices) at the High-
throughput Screening Facility, School of Chemical Sciences at the University of Illinois. 
GraphPad Prism 4 software was used for analysis of DNA binding. 
Complementation tests.  
Complementation of strain BM4092 (9) transformed with plasmids pSKH26, 
pSKH27, pSKH28, pSKH29 or pSKH30 was tested as described previously (54). The 
strains were grown at 37°C on glycerol M9 minimal plates (66) containing 
chloramphenicol and various concentrations of biotin (4 nM, 40 nM, 400 nM) (9). Strain 
BM4092 carrying pSKH30 was also grown with 25 µM 5-bromo-4-chloro-indolyl-β-D-
galactopyranoside (X-gal). 
DNA sequence alignments.  
Sequence alignments were obtained using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) and the output was processed by ESPript 3.0 
(http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi) to generate the final figure (49). 
 
Results 
S. aureus BirA binds the B. subtilis bioO operator and modifies the B. subtilis acceptor in 
vitro.  
For simplicity we will call the S. aureus BPL SaBirA where SaBirA will be used 
in the formal sense as the primary translation product lacking biotin and Bio-AMP. The 
SaBirA form containing biotin is called SaBirA(btn), that containing ATP as 
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SaBirA(ATP) and that containing Bio-AMP as SaBirA(Bio-AMP). Note that Mg++ is 
always present in the latter two cases. 
To assess the possibility that the B. subtilis bioO strain constructed previously 
(54) could be used to test in vivo regulation by SaBirA, we asked if SaBirA is capable of 
binding B. subtilis bioO. The protein was purified (Figure 3.2) and electrophoretic 
mobility shift assays (EMSAs) were performed (Figure 3.3B). SaBirA bound the B. 
subtilis bioO binding site in the presence of biotin and ATP (e.g., as SaBirA(Bio-AMP) 
whereas low levels of DNA binding were observed for SaBirA and SaBirA(btn) samples 
which suggested that some of the protein had the biotinoyl-AMP intermediate bound in 
the active site. SaBirA(ATP) bound the operator almost as well as SaBirA(Bio-AMP) 
suggesting that the untreated, as purified, BirA had biotin bound in the active site. This 
was surprising because biotin was reported to readily dissociate from SaBirA (86). A 
similar co-purification of biotin with the protein was previously observed with B. subtilis 
BirA (54). We also assayed SaBirA for the ability to biotinylate AccB-86, the C-terminal 
biotin accepting domain of B. subtilis AccB (54), by transfer of biotin from Bio-AMP 
assayed by thin layer chromatography (Figure 3.3C) and by mass spectral analysis of 
AccB-86 biotinylation (Figure 3.4). The ability of SaBirA to function with the B. subtilis 
components indicated that the regulatory properties of the S. aureus protein could be 
tested with this system. 
In vivo SaBirA responds to biotin and acceptor protein levels.  
To assay the regulatory properties of SaBirA we modified the B. subtilis strain 
used previously (54) by replacement of the B. subtilis birA with the S. aureus birA. The 
strain also contained a bioB141 mutation that causes biotin auxotrophy plus a bioW-lacZ 
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fusion that allows measurement of bio operon transcription by β-galactosidase assays. 
The new strain was grown in defined media supplemented with kanamycin, 
erythromycin, licomycin and various concentrations of biotin. As the biotin concentration 
increased the level of bioW-lacZ transcription decreased indicating SaBirA mediated 
transcriptional repression of the biotin operon in response to biotin levels (Figure 3.5A). 
We also tested regulation of the biotin operon by SaBirA in response to the level of the B. 
subtilis AccB-86 acceptor protein. This required a modification of the SaBirA-B. subtilis 
strain by introduction of an ectopic IPTG-inducible gene encoding the AccB-86 acceptor. 
This strain was grown as above with various concentrations of biotin. Upon induction of 
AccB-86 production β-galactosidase assays showed that expression of the biotin operon 
became derepressed at biotin concentrations that normally give repression (Figure 3.5B). 
These results parallel those seen in E. coli and B. subtilis upon overproduction of 
acceptor proteins (1, 26, 38, 54, 87). Therefore, the SaBirA protein is a fully functional 
regulatory ligase which raised the question of how to explain the conflicting in vitro 
results reported by Soares da Costa and coworkers (85) 
In vitro DNA binding of S. aureus BirA to S. aureus bioO.  
The as purified SaBirA bound the S. aureus bioO probe in EMSA analysis 
without additions of biotin or ATP (Figure 3.6A). The as purified SaBirA plus either 
biotin or ATP also bound the probe. This could not be attributed to non-specific DNA 
binding activity because a probe of unrelated sequence showed no shifts (Figure 3.6A). 
These data indicated that as purified SaBirA had acquired biotin from the E. coli host and 
converted at least some to Bio-AMP. To rid the protein of these ligands we incubated the 
as purified SaBirA with ATP and MgCl2 to convert any biotin to Bio-AMP. We then 
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treated the protein with neutral hydroxylamine to cleave any biotinoyl-AMP to give AMP 
plus biotinoyl hydroxamate. Following this treatment SaBirA no longer bound the 
operator DNA in the presence or absence of biotin (Figure 3.6B). However DNA binding 
activity was still observed for the treated SaBirA in the presence of ATP, a surprising 
result in that biotin was shown to be required for binding of ATP-Mg++ by SaBirA (86). 
Incubation with an excess of the AccB-86 acceptor protein failed to prevent the ATP-
dependent shift (Figure 3.6C). These results argued that either biotin was still bound in 
the SaBirA active site or that it was not required for the observed mobility shift. We 
tested these hypotheses by assay of the protein samples for biotin using a sensitive 
bioassay that can detect as little as 1 pmol of biotin. 
Samples of the as purified and treated SaBirA were denatured and centrifuged. 
The supernatants were spotted on paper disks in sectored minimal plates containing a 
redox indicator and the E. coli biotin auxotroph NRD25 which contains a complete 
deletion of the bio operon (Figure 3.7). As expected the as purified SaBirA samples 
contained biotin (or Bio-AMP which would be hydrolyzed to biotin in the protein 
denaturation step). This was surprising because prior workers reported a rapid off rate for 
biotin as measured by surface plasmon resonance analyses (86). In contrast the treated 
SaBirA contained no detectable biotin or Bio-AMP even when large amounts of the 
protein were assayed. As a control we incubated the treated SaBirA with an equimolar 
concentration of biotin. Upon denaturation and bioassay the expected level of biotin was 
detected indicating that the protocol did not interfere with the release of biotin into the 
supernatant. The bioassays confirmed that incubation of SaBirA with ATP and MgCl2 
prior to neutral hydroxylamine treatment effectively removed biotin from the as purified 
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SaBirA preparations. This raised the question why the EMSA analyses detected DNA 
binding activity for the SaBirA(ATP) when no biotin was present. One possibility was 
that binding was an artifact of the EMSA analyses (21, 22, 46-48).  
To test this possibility we turned to a florescence anisotropy assay that allowed 
DNA binding to be measured in free solution. SaBirA, SaBirA(btn), SaBirA(ATP) and 
SaBirA(Bio-AMP) samples were prepared from the as purified protein as described in 
Experimental Procedures. These preparations were then assayed for DNA binding 
activity by EMSA using the buffer conditions given by Soares da Costa and coworkers 
(85) (Figure 3.6D). The DNA binding activities of four SaBirA protein samples were 
tested with a fluorescein end-labeled 33 base pair S. aureus bioO binding site. The 
changes in anisotropy were plotted against the protein concentrations to obtain binding 
curves and the data were analyzed using the non-linear curve fitting function of 
GraphPad Prism 4 to calculate Kd values (Figure 3.8). The SaBirA and SaBirA(ATP) 
samples had very high Kd values of 5.284 ± 0.23 µM and 7.841 ± 1.1 µM, respectively, 
values that differed greatly from the SaBirA Kd value of 649 ± 43 nM reported from 
EMSA data by Soares da Costa and coworkers (85). Unexpectedly, SaBirA(btn) had the 
appreciably lower binding Kd of 182.8 ± 10.97 nM. As expected, SaBirA(Bio-AMP) 
sample had the lowest Kd. A value of 83.1 ± 4.2 nM was found which is similar to that 
previously derived from EMSA data (85). Note that in the case of E. coli BirA, a major 
component of the 2000-fold difference in operator binding of the BirA:Bio-AMP 
complex versus the unliganded protein is that the unliganded BirA has essentially no 
dimerization ability (equilibrium dimerization constant of 1−2 mM) (90). In contrast, 
unliganded SaBirA has an equilibrium dimerization constant of 29 µM (85). 
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If unliganded E. coli BirA had the dimerization ability of SaBirA a rough calculation 
suggests that the difference in binding affinities of the unliganded and Bio-AMP liganded 
proteins would be comparable to those of SaBirA and SaBirA(Bio-AMP). 
SaBirA requires N-terminal domain sequences for full ligase activity.  
E. coli BirA was recently shown to require specific interdomain interactions for full 
ligase activity (25). The wing of the winged HTH structure interacts with the biotin 
binding loop of the ligase active site and acts to organize the active site to give high 
affinity binding of biotin and biotinoyl-AMP (25). Unlike E. coli, B. subtilis BirA does 
not require an intact N-terminal DNA binding domain for full ligase activity (54). We 
previously modeled the B. subtilis BirA structure on the SaBirA BirA crystal structure 
(PDB 4DQ2) because among the biotin ligase proteins of known structure that protein 
had highest amino acid sequence identity (31%) to B. subtilis BirA. Based on this 
modeling we expected that deletions of the SaBirA N-terminal domain would retain 
ligase activity as did N-terminal domain deletion derivatives of the B. subtilis protein 
(54). To test this expectation we constructed N-terminal deletions of three different 
lengths as previously done for B. subtilis BirA (54). SaBirA deletion Δ2-65 eliminated 
the N-terminal domain whereas SaBirA deletions Δ2-74 and Δ1-81 cut into the central 
domain (Figure 3.9). 
Complementation assays using the E. coli birA1 strain BM4092 (9) were used to test 
the ligase activity of the three SaBirA N-terminal deletion proteins. All three N-terminal 
deleted S. aureus BirAs failed to restore ligase activity to the E. coli mutant strain at low 
biotin concentrations (Figure 3.10A). However at higher biotin concentrations the Δ2-65 
construct allowed markedly better growth than the empty vector indicating that the 
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protein was expressed and stable. To determine if, like E. coli BirA, the wing of the HTH 
structure was important for active site organization we constructed a Δ48-63 wing 
deletion and tested the activity of this protein by complementation of the E. coli birA 
mutant strain. The wing deletion protein failed to complement ligase activity at low biotin 
concentrations although at higher biotin concentrations expression of the protein largely 
restored ligase activity (Figure 3.10B) as seen with the E. coli wing deletion BirA (25). 
As expected from the differing operator sequences, the blue colonies formed by the wild 
type SaBirA indicated that the protein was unable to regulate E. coli bio operon 
transcription.  
 
Discussion 
The BirA proteins of E. coli and B. subtilis provide a simple, yet sophisticated, 
regulatory system that monitors both intracellular biotin supply and the levels of enzyme 
proteins that require biotinylation for activity (1, 12, 34, 54). This is accomplished by use 
of the intermediate in the ligase reaction, Bio-AMP, as the regulatory ligand. Only when 
the active site is occupied by Bio-AMP do the proteins efficiently dimerize and thereby 
acquire the ability to bind their cognate operator sequences. Soares da Costa and 
coworkers (85) reported the surprising result that SaBirA dimerizes and binds its operator 
in the absence of substrates/ligands with an affinity only 6-fold lower than the affinity of 
the Bio-AMP complex. This is in contrast to the E. coli BirA where the operator binding 
affinity of the unliganded protein is 2000-fold lower than the Bio-AMP complex as 
measured by nuclease footprinting (90). Such sensitive methods have yet to be applied to 
B. subtilis BirA, but the available data argue that the Bio-AMP complex has an affinity 
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for its operators at least 50-fold greater than the unliganded protein. Physiologically the 
ability of unliganded SaBirA to bind its operator would result in decreased bio operon 
transcription and transport even when biotin was limiting. Moreover, the cell would be 
unable to respond to unmodified acceptor protein levels and central metabolism would be 
compromised. Indeed, the unliganded protein could behave much as a dominant negative 
mutant protein by blocking binding of SaBirA(Bio-AMP) to the operator. 
Our in vivo data demonstrate that this perverse scenario does not occur. SaBirA is 
a competent regulatory protein that responds to both biotin supply and the levels of apo 
acceptor protein (Figure 3.5). These results raised the question of how the results of Costa 
and coworkers (85) could be rationalized. The short answer is that EMSA analysis of 
interaction of SaBirA with its operator is rife with artifacts. For example we found that 
ATP-Mg++ elicits operator binding in the absence of biotin (Figure 3.6) although surface 
plasmon resonance measurements indicate that the protein cannot bind ATP-Mg++ under 
these conditions (86). The reported binding of unliganded SaBirA to its operator (86) also 
seems an artifact of their EMSA conditions since we could detect no binding in our 
EMSA analyses (Figure 3.6) and only very weak binding by fluorescence anisotropy 
(Figure 3.8). 
Although EMSA analyses are often considered straightforward, it is well 
documented that EMSA conditions can stabilize interactions that are weak in solution 
(47, 48). Three overlapping mechanisms have been put forth to rationalize such results. 
These are interactions with the gel matrix that stabilize protein-DNA affinities, the cage 
effect and sequestration. The latter two mechanisms have received experimental 
verification. The cage effect is the inability of dissociated molecules to diffuse 
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sufficiently far away from one another to prevent reassociation (21, 22). This effect has 
been demonstrated for LacI repressor-operator interactions (46, 47). Sequestration is the 
decreased solution volume accessible to the protein and DNA which increases the 
effective concentrations of the components thereby promoting interaction. Sequestration 
has been demonstrated for interaction of the E. coli cyclic AMP receptor protein with its 
binding site on the Lac promoter (48). The opposite effects have also been reported. The 
E. coli tryptophan (TrpR) repressor binds its operator at pH 8.3 as shown by nuclease 
footprinting although no gel shift was seen at this pH (23).  
The binding measurements we obtained in free solution accurately reflect the 
mechanism of the regulatory system in vivo. Indeed, the behavior of the regulatory 
system in vivo must be the litmus used to judge the relevance of in vitro measurements. 
The binding curves obtained by fluorescence anisotropy indicated that SaBirA and 
SaBirA(ATP) bind DNA much more weakly than SaBirA(Bio-AMP). However, 
SaBirA(btn) binding was comparable to that of SaBirA(Bio-AMP) with only a modest 
decrease in DNA binding affinity. This interesting result suggests that biotin alone may 
be sufficient for dimerization and DNA binding and play a role in the regulatory 
mechanism. However, the finding that high level production of an acceptor protein 
derepresses transcription at high biotin concentrations argues against this suggestion 
because SaBirA(Bio-AMP) is required for protein modification. We view the 
SaBirA(btn) dimerization as facilitating Bio-AMP synthesis and dimerization by raising 
the local concentration of biotin-bound monomer and structuring the ATP binding site. 
Efficient operator binding in the presence of biotin has not been observed for E. coli 
BirA. Relative to the Bio-AMP complex the biotin complex binds the operator 100-fold 
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(75) or 146-fold (90) less tightly. Much of this difference is due to the weak dimerization 
elicited by biotin binding (90). In EMSA analyses neither B. subtilis BirA (54) nor 
SaBirA (Figure 3.6) showed significant operator binding in the presence of biotin. A 
possible explanation is that due to its charge biotin may electrophorese away from the 
protein. 
Contrary to our expectations deletion of SaBirA N-terminal domain sequences 
gave results that paralleled those of the analogous E. coli BirA deletions (25, 100) rather 
than those of the more highly sequence and taxonomically related B. subtilis BirA (54). 
Therefore, SaBirA like E. coli BirA requires interdomain communication for full ligase 
activity. It would be interesting to compare the S. aureus and B. subtilis BirA regulatory 
efficiencies under conditions where each protein has the same level of expression and 
bind its cognate operator.  
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Tables 
Table 3.1. Strains used in this chapter. 
Strain Relevent Genotype or Description 
Reference or 
Derivation 
B. subtilis     
1A330 aroG932, bioB141 
Bacillus Genetic 
Stock Center 
SKH001 1A330, bioW::lacZ ermR (54) 
SKH002 SKH001 amyE:: P spac accB-86 spcR (54) 
SKH003 
SKH001, B. subtilis birA::S. aureus birA 
kanR This study 
SKH004 
SKH002, B. subtilis birA::S. aureus birA 
kanR This study 
E. coli      
BL21 Star 
(DE3) ompT hsdSB rne131 (DE3) Novagen 
NRD25 MC1061, bioABFCD::CmR  (31) 
BM4092 Δ(argF-lac)169 TP(bioF-lacZ)501 (9) 
 
Table 3.2. Plasmids used in this chapter. 
Plasmid Relevent Genotype or Description 
Reference or 
Derevation 
pET28b T7 promoter expression vector, KanR Novagen 
pSKH025 pET28b encoding S. aureus BPL This study 
pBAD322Cm copy control expression vector, CmR Cronan, 2006 
pSKH026 pBAD322Cm encoding WT S. aureus BPL This study 
pSKH027 pBAD322Cm encoding Δ2-65 S. aureus BPL This study 
pSKH028 pBAD322Cm encoding Δ2-74 S. aureus BPL This study 
pSKH029 pBAD322Cm encoding Δ2-81 S. aureus BPL This study 
pSKH030 
pBAD322Cm encoding Δ48-63 S. aureus 
BPL This study 
pDG780 
Kanamycin-resistance cassette for Bacillus 
subtilis, BGSCID: ECE93 
Bacillus Genetic 
Stock Center 
pDG780-panB  pDG780 with 500 bp after B. subtilis BirA This study 
pSKH031 
pDG780-panB encoding last 500 bp cca and 
S. aureus BPL This study 
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Table 3.3. Oligonucleotide primers used in this chapter.  
Oligo-
nucleotide Description Sequence 
SKH014 Bs bioO F GATCCTTTCTTCTATTGACAGAAAC 
SKH015 Bs bioO R CGC CCTTTCACTGATAACTGAAGAAC 
SKH028 Non 125 F GCATGACGGTTAGCATACAAATGGCAG 
SKH029 Non 125 R AACGATCGGGATTTCCATTTTCATCGATTC 
SKH076 SaBPL F PciI 
GTACATGTCAAAATATAGTCAAGATGTAC
TTCAATTACTC 
SKH077 SaBPL R XhoI 
CCAGTCTCGAGAAAATCTATATCTGCACTA
ATTAAACGGT 
SKH078 
SaBPL F delta 
2-65 BspHI AGTCATGATTTGGTATCAAGGTATAATAG 
SKH079 
SaBPL F delta 
2-74 PciI GTACATGTATACAAAAAGTTCTGCTTTG 
SKH080 
SaBPL F delta 
2-81 PciI GTACATGTTTGATTTTAGTGAAGTATACG 
SKH081 SaBPL R SalI ACGTGTCGACTTAAAAATCTATATCTGCAC 
SKH097 
SaBPL 1-141 R 
overlap 
AAATATCTGGGCCTCCCTCTAACTTTAATT
GGTC 
SKH098 
SaBPL 190-972 
F overlap 
GTTAGAGGGAGGCCCAGATATTTGGTATC
AAGG 
SKH099 Sa bioO F TACTGAGAAGTTTAAATTCATGTTTTCTTG 
SKH100 Sa bioO R 
TCGTACTTGTAATAAAAATCCTCATAAAA
ATAAC 
SKH102 PanB 500 F SalI 
ACGTGTCGACTAATGTGTTGGTACAAGCC
CGTTGA 
SKH103 
PanB 500 R 
XhoI 
ACGTACTCGAGCGGCATATCTGTCACAAT
AAAGG 
SKH104 
cca 500 F 
BamHI 
ACGTGGATCCTTTTATCATAAACGAGAAA
ACCTG 
SKH105 
cca 500 R 
SaBPL overlap 
ATATATTTTGACATGTCTTCAGCCACTCCT
CTATGTG 
SKH106 
SaBPL F cca 
overlap 
GTGGCTGAAGACATGTCAAAATATATAAA
AGATGTAC 
SKH107 SaBPL R EcoRI 
ACGTGAATTCTTAAAAATCTATATCTGCAC
TAATTAAAC 
SKH134 SaBPL seq F TTGTGACAGGGAAGCTCTCC 
SKH135 SaBPL seq R CCTCATCCTCTTCATCCTCTTCG 
SKH162 
6-F sense Sa 
bioO 
56-
FAM/AATGTAAACTTATTAATTATAAAAGT
TTACATT 
SKH163 
Antisense Sa 
bioO 
AATGTAAACTTTTATAATTAATAAGTTTAC
ATT 
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Figures 
 
Figure 3.1. The biotin protein ligase reaction, current model of E. coli BirA 
regulation. A. BirA binds both biotin and ATP to synthesize biotinoyl-AMP with release 
of pyrophosphate. The mixed anhydride bond of biotinoyl-AMP then undergoes 
nucleophilic attack from the ε-amino group of the conserved lysine residue of the 
acceptor protein resulting in covalently attached biotin and free AMP. B. Repression. 
Sufficient biotin is present and essentially all acceptor protein (AccB) is biotinylated. C. 
Limited biotin results in low levels of Bio-AMP such that BirA is unable to dimerize and  
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Figure 3.1. (cont.) 
exert repression. D. An excess of AccB acceptor protein consumes the Bio-AMP 
resulting in low levels that preclude dimerization and repression. Green ovals denote  
BirA, tailed blue ovals are AccB, black dots represent biotin, and black dots with red 
pentagons denote biotinoyl-adenylate (Bio-AMP).  
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Figure 3.2. Purification of S. aureus C-terminal His-tagged BirA. The SaBirA was 
purified as described in Experimental Procedures and subjected to SDS-electrophoresis 
on a 12% polyacrylamide gel. M: molecular weight standards (Precision Plus Protein 
Standard Kaleidoscope from BioRad), UN: uninduced whole cell lysate, IN: induced 
whole cell lysate, S: clarified lysate, F: flow though, W1: wash fraction one, W2: wash 
fraction 2, W3: wash fraction 3, E1: elution fraction 1, E2: elution fraction 2. 
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Figure 3.3. S. aureus BirA binds B. subtilis bioO and modifies AccB-86. A. Sequence 
alignments of B. subtilis bioO, S. aureus bioO, and S. aureus bioY DNA binding sites. 
The SaBirA DNA binding sites are almost identical to the B. subtilis bioO binding site. 
Only a single base in each B. subtilis bioO half site differs from those of both S. aureus 
operators. Conserved nucleotides are in white text and highlighted in red. Half site 
binding regions are indicated with the black arrows. B. EMSA showing S. aureus BirA 
binding to B. subtilis bioO. Note the small shift seen for BirA only and BirA with biotin 
only samples and the large shift seen for the BirA with ATP only sample. C. In vitro 
biotinylation thin layer chromatographic assay of biotin transfer from S. aureus BirA to 
the B. subtilis acceptor protein AccB-86. Transfer is detected by the production of AMP 
(Figure 3.1A) plus consumption of ATP. 
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Figure 3.4. MALDI Mass spectral analysis of the SaBirA ligase catalyzed 
biotinylation of B. subtilis AccB-86. Panel A shows the purified AccB-86. The reaction 
of Panel B did not go to completion. The peaks upstream of the apo and holo are adducts 
formed by salts of the reaction mixture (AccB-86 is an unusually acidic protein). The 
calculated and determined masses for apo AccB-86 were 9418.7 and 9415.1, 
respectively, whereas the calculated and determined masses for holo AccB-86 were 
9644.7 and 9640.8, respectively. 
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Figure 3.5. S. aureus BirA responds to biotin and apo acceptor protein levels. A. β-
Galactosidase assays of the effects of biotin concentration on bioO-dependent 
transcription. The biotin requiring strain was grown in defined medium supplemented 
with the indicated concentrations of biotin. Error bars denote SEM. B. β-Galactosidase 
assays of the effect of B. subtilis AccB-86 expression on bioO-dependent transcription. 
The strain was grown in defined medium supplemented with the indicated concentrations 
of biotin in the presence or absence of IPTG. Note the increase in some biotin 
concentrations in panel B. Error bars denote SEM. 
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Figure 3.6. Electrophoreteic Mobility Shift Assay of SaBirA DNA binding to S. 
aureus bioO. A. SaBirA binding to S. aureus bioO (lanes 1-5) or to a nonspecific DNA 
sequence (lanes 6-10). B. SaBirA was incubated with ATP and then treated with neutral 
hydroxylamine to remove any biotinoyl-AMP intermediate. C. SaBirA was incubated 
with ATP and B. subtilis AccB-86 to remove any biotin or Bio-AMP from the active site. 
D. SaBirA was incubated with either biotin (lanes 2-5) or ATP (lanes 7-10) and then 
treated with neutral hydroxylamine to remove any intermediate formed. Note the binding 
conditions were modified to those used by Soares da Costa and coworkers (85) (the 
composition of the gels utilized was not reported). 
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Figure 3.7. Treatment with hydroxylamine effectively removes Bio-AMP from 
SaBirA. A. Biotin standards. B. Recovery of biotin from a mixture of biotin and 
hydroxylamine-treated SaBirA. C. The as purified SaBirA contains either biotin or Bio-
AMP. D. - E. After incubation without (D) or with ATP plus MgCl2 (E) the samples 
were treated with neutral hydroxylamine followed by hydroxylamine removal. The 
protein samples were then denatured and the supernatants assayed for biotin. In the 
absence of ATP any bound biotin present would retain its free carboxyl group and be 
active in the bioassay whereas the biotin moiety of Bio-AMP (either formed from bound 
biotin in the presence of ATP or bound to the as purified protein) would be inactive in the 
bioassay due to its blocked carboxyl group. The lack of bioassay activity in the sample 
lacking ATP indicates the absence of bound biotin. Hence, the bound biotin must be in 
the form of Bio-AMP. Excepting the biotin standards plate the pmol values given 
correspond to the amount of protein denatured. 
  
	 82	
 
Figure 3.8. Binding isotherms of SaBirA binding to S. aureus bioO obtained by 
fluorescence anisotropy. A. SaBirA(Bio-AMP) gave a dissociation constant of 83.1 ± 
4.2 nM. B. SaBirA(btn) gave a dissociation constant of 182.8 ± 10.97 nM. C. SaBirA 
gave a dissociation constant of 5.284 ± 0.23 µM. D. SaBirA(ATP) gave a dissociation 
constant of 7.841 ± 1.1 µM. Note the differing abscissa protein concentrations.   
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Figure 3.9. S. aureus BirA N-terminal deletions. The wing that was deleted (Δ48-63) is 
shown in cyan. The end point of N-terminal deletion Δ2-65 is shown in yellow. The end 
point of N-terminal deletion Δ2-74 is shown in red whereas that of N-terminal deletion 
Δ2-81 is shown in orange. The image was created from the PDB file (4DQ2) using UCSF 
Chimera (74).  
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Figure 3.10. Growth of E. coli strain BM4092 supported by expression of S. aureus 
BirA and its N-terminal deletions. A. Strains were grown on glycerol M9 minimal 
media with biotin (4 nM, 40 nM or 400 nM). B. Strains were grown on glycerol M9 
minimal media with biotin (4 nM, 40 nM or 400 nM) and X-gal. Glucose represses the 
arabinose promoter to give a low level of expression consistent with the low expression 
of BirA proteins. The blue color indicates derepressed transcription of the bioF-lacZ 
fusion. Note that S. aureus wild type BirA does not complement E. coli BirA regulatory 
function. 
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Chapter 4 
Conclusions 
 
Lessons Learned from Bacillus subtilis 
 The objective of this thesis was to investigate other group II BPLs to determine if 
they follow E. coli BirA regulatory properties and interdomain communication 
characteristics. Before this study, other group II BPLs were predicted based on the helix 
turn helix motif in the N-terminal domain. The regulatory properties of these predicted 
group II BPLs were untested but expected to follow the E. coli BirA model of 
transcriptional regulation of the biotin operon. However, the predicted group II BPLs 
have low sequence identity to E. coli BirA, have multiple predicted DNA binding sites, 
have different biotin synthetic genes, and contain multiple biotin dependent enzymes. 
This study examined other examples of group II BPLs to determine if these differences 
add a layer of complexity to the regulatory function.  
 The E. coli BirA requires the wing of the helix turn helix motif of the N-terminal 
DNA binding domain for proper ligase activity. This requirement is surprising for two 
reasons. First, the crystal structure of the E. coli BirA indicates that the N-terminal 
domain is separated from the catalytic central domain by a linker region. Second, group I 
BPLs do not have an N-terminal DNA binding domain and still have adequate ligase 
activity. This study looked to determine if other group II BPLs require interdomain 
communication between the N-terminal DNA binding domain and the central catalytic 
domain for proper ligase activity.  
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In Chapter 2, I studied the group II BPL from B. subtilis. Purified B. subtilis BirA 
binds to the three predicted DNA binding sites only in the presence of both biotin and 
ATP. This indicates that the co-repressor is the intermediate biotinoyl-AMP, as seen for 
E. coli BirA. Similar to E. coli BirA, B. subtilis BirA only dimerizes significantly in the 
presence of both biotin and ATP. In E. coli, homodimerization of BirA is required for 
DNA binding to occur. In vivo transcriptional analysis of the biotin operon indicates that 
B. subtilis BirA responds to both biotin concentration and apo biotin acceptor protein 
levels. These two characteristics are fundamental to the E. coli BirA regulatory model. 
Although the B. subtilis BirA has low sequence identity to E. coli BirA, has three DNA 
binding sites, and has three biotin acceptor proteins, B. subtilis BirA follows the E. coli 
BirA regulatory model.  
I also studied the role of the N-terminal DNA binding domain in the ligase 
activity of B. subtilis BirA. Using a structural model of B. subtilis BirA based on the 
crystal structure of S. aureus BirA, I determined end point residues for N-terminal 
deletions. Ligase activity was determined for the N-terminal deletions first by a 
complementation assay using an E. coli strain with a BirA mutant. Complementation was 
observed for several of the N-terminal deletions. Purification of these N-terminal 
deletions and in vitro biotinylation assays further showed that the B. subtilis BirA could 
successfully be converted into a group I BPL. Unlike E. coli, this indicates that the B. 
subtilis BirA does not require interdomain communication between the N-terminal DNA 
binding domain and the central catalytic domain for proper ligase activity.  
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Lessons Learned from Staphylococcus aureus 
In Chapter 3, I studied the group II BPL from S. aureus. It was reported that S. 
aurues BirA could dimerize and bind DNA in the absence of biotin and ATP. This was 
surprising since E. coli and B. subtilis group II BPLs require both biotin and ATP for 
dimerization and subsequent DNA binding. Without the requirement of biotin and ATP 
binding for dimerization and DNA binding, S. aureus BirA would not be an effective 
regulator of the biotin operon. Repression of the biotin operon would occur without 
regard for the biotin concentration or the level of apo acceptor protein. Using the biotin 
operon transcriptional test strain I created for B. subtilis, I was able to test S. aureus BirA 
regulation in vivo. S. aureus BirA does respond to both biotin concentration and 
increased levels of apo acceptor protein, similar to E. coli and B. subtilis BirA. It was 
then important to determine why S. aureus BirA DNA binding activity was observed in 
the absence of biotin in vitro in EMSA. To determine if the EMSA gel matrix was giving 
in vitro artifacts we decided to use a solution-based method. Using fluorescence 
anisotropy I was able to generate DNA binding curves for S. aureus BirA in the presence 
and absence of biotin and ATP. These binding curves corroborate the results obtained 
from the in vivo transcriptional test strain. Surprisingly, the biotin alone had a similar 
DNA binding affinity compared to biotinoyl-AMP. This result was not seen for S. aureus 
BirA using EMSA and biotin only DNA binding has not been observed for E. coli or B. 
subtilis BirA. However, fluorescence anisotropy has not been used to determine DNA 
binding for E. coli or B. subtilis BirA in the presence of only biotin. 
I also tested the role of the S. aureus BirA DNA binding domain in the enzymatic 
activity of the protein. Because the crystal structure of S. aureus was used to model the B. 
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subtilis BirA, we expected that deletion of the N-terminal domain would not affect ligase 
activity. To our surprise, deletion of the DNA binding domain resulted in severely 
decreased ligation activity as was previously observed with E. coli BirA. Furthermore, 
deletion of the wing from the helix-turn-helix motif in the DNA binding domain also 
severely decreased ligase activity. This indicates that like E. coli BirA, the wing is 
playing a role in active site organization.  
 
Future Directions 
 Future work will investigate the two annotated biotin protein ligases from 
Clostridium acetobutylicum (79). Sequence alignments of C. acetobutylicum BPLs Ca 
0212 and Ca 0589 to E. coli BirA show that Ca 0212 is a group II BPL, BirA, that is 
lacking the conserved C-terminal domain and that Ca 0589 is a group I BPL (Figure 4.1). 
Three Ca 0212 DNA binding sites have been predicted based on sequence alignments and 
are found near putative biotin biosynthetic genes or putative biotin transport genes 
(Figure 4.2) (79). Future work will determine if both C. acetobutylicum BPLs have ligase 
activity and if Ca 0212 has regulatory function as predicted by sequence alignments. It is 
unclear why C. acetobutylicum would need two BPLs, thus it will be interesting to 
determine if each protein has evolved specialized functions. Previous work showed that 
the two F. novicida BPLs have distinct roles (45). BplA, a group I BPL, is the more 
efficient enzyme that is required for pathogenicity, whereas the main role of the other 
BPL, BirA, is to prevent wasteful biotin synthesis (45).  
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Figures 
 
Figure. 4.1. Sequence alignments of E. coli BirA, C. acetobutylicum BPL 0212, and 
C. acetobutylicum BPL 0589. C. acetobutylicum BPL 0212 (Ca 0212) has 25% sequence 
identity to E. coli BirA and 40% sequence identity to C. acetobutylicum BPL 0589 (Ca 
0589). Ca 0589 has 22% sequence identity to E. coli BirA. Conserved residues are in 
white text and highlighted in red and similar residues are in red text and boxed in blue. 
The E. coli BirA secondary structure (PDB: 1HXD) is shown above the amino acid  
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Figure 4.1. (cont.) 
sequence. Note that Ca 0212 is missing the conserved C-terminal domain and Ca 0589 is 
missing the N-terminal DNA binding domain.  
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Figure 4.2. Predicted C. acetobutylicum BPL 0212 DNA binding sites. C. 
acetobutylicum BPL 0212 has three predicted DNA binding sites near putative biotin 
biosynthetic genes or putative biotin transport genes. Note that one binding site is located 
near bpl Ca 0212 indicating self-regulation may occur.  
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